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AIM 
To study the change in scar grading following healing of a corneal ulcer over one year 
and its effect on visual function. 
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OBJECTIVES 
PRIMARY OBJECTIVE 
To study the change in scar grade over 1 year following healing of a suppurative corneal 
ulcer.  
SECONDARY OBJECTIVES 
1. To study the visual function (visual acuity, stereopsis and binocular visual field, glare 
acuity) in patients who have been treated in our department for infective keratitis 1 year 
(prospective arm) to 2 years (Retrospective arm) after complete healing of a corneal 
ulcer. 
 
2. To study the subjective need for corneal transplantation following an episode of 
infective keratitis. 
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INTRODUCTION 
 
Infective keratitis, or corneal ulcer, is a major cause of ocular morbidity in our country.  
The active infection in most corneal ulcers respond well to rational and adequate 
treatment, but heal with different degrees of residual corneal scarring. This residual scar 
is a major cause of corneal blindness and effective visual rehabilitation usually requires a 
corneal transplant. 
Considering the large numbers of patients who present to our institution with severe 
corneal ulcers, we would expect a majority of these patients requesting corneal 
transplantation for visual rehabilitation. However, we have found that a large number of 
these patients do not actually want a corneal transplant done.  
Some of the reasons may be due to cost factors related to socioeconomic status of the 
patients or inability of the patients to come for regular close follow-ups required after the 
transplant. 
Other factors may be due to presence of good vision in the fellow eye, which allows the 
patient continue his life with minor adjustments to monocular vision. 
Additionally, re-modeling of the corneal scar may actually reduce the scar intensity, 
allowing recovery of some vision in that eye. 
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Thus, this study was undertaken in order to assess the scar characteristics, and the 
possible reasons why many patients do not opt for corneal transplantation to improve 
vision. 
This was a Prospective study composed of two cohorts of patients with healed 
suppurative corneal ulcer:  
1. Prospective Cohort:  
Patients with corneal ulcers who fulfilled the inclusion criteria, seen in our 
department from 1
st
 February 2016 to  31
st
 July 2016 were recruited after the ulcer 
healed. Full ophthalmic evaluation was performed. The grade of the scar and 
visual function (visual acuity, binocular visual field, stereopsis, glare acuity) was 
recorded. These patients were followed up at 3 months, 6 months and 1 year in 
order to determine any change that may occur over one year.  
2. Retrospective Cohort:  
Patients who had previously been admitted in our corneal ulcer ward from 1
st
 
February 2014 to 31
st
 December 2015 who fulfilled the inclusion criteria were 
contacted and called back for a full ophthalmological evaluation and visual 
function assessment. These patients were also followed up at 3 months, 6 months 
and 1 year, as applicable based on the duration after healing at in the time of 1
st
 
examining the patient, in order to determine any change that may occur over one 
year.  
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At the end of the follow-up period for each patient, a questionnaire was administered in 
order to determine the influence of social factors, Socioeconomic score (SES) and visual 
requirements. 
Data was also collected regarding the subjective attitude of the patient regarding their 
need for a corneal transplant. 
 In those patients who did not want a corneal transplant, the reasons for this decision was 
also sought. 
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LITERATURE REVIEW 
The cornea is the transparent anterior coat of the eye covered with the tear film 
anteriorly and bathed in aqueous posteriorly. The junction of the cornea with the 
sclera, the limbus is a highly vascularized region, rich in pluripotent stem cells which 
are present in the palisades of Vogt at the limbus. The palisades of Vogt are a series of 
radially oriented fibrovascular ridges that are concentrated around the superior and 
inferior limbus just peripheral to the terminal capillary loops of the limbus and central 
to the schlemm’s canal. The palisades and inter palisade regions contains specialized 
blood vessels and are repositories of epithelial cells, which may play a role in 
replacing defective epithelial cells.  (1) 
The cornea consists of five layers- epithelium, Bowman’s layer, stroma, Descemet’s 
membrane and endothelium. The normal healthy cornea is avascular and devoid of 
lymphatic channels. The nourishment for the cornea is derived from diffusion from the 
aqueous, the limbal capillaries and oxygen dissolved in the tear film. (2) 
 
FACTORS CONTRIBUTING TO TRANSPARENCY OF THE CORNEA 
The transparency of the cornea is maintained by its relatively dehydrated state, the 
absence of blood vessels and pigment, and the uniform refractive index of all the 
layers as well as the uniform spacing and size of the collagen fibrils in the stroma. (2) 
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Corneal transparency depends heavily on the highly complex levels of organization as 
well as the regular spatial arrangement of the uniformly thin collagen fibrils making up 
the stromal layer. The collagen fibrils measure approximately 25–35 nm in diameter. 
Collagen fibrils form parallel bundles and extend from limbus to limbus, and these 
bundles are arranged in layers or lamellae. They lie closely arranged, parallel to each 
other in layers (lamellae) 200–250 nm thick.(3) The collagen fibrils have diameters 
less than the wavelength of light and a refractive index close to the ground substance. 
Thus scattering of light due to these fibrils is minimal.  
The collagen fibrils are packed more densely in the anterior two-thirds and axial cornea, 
compared to the peripheral cornea.  
The anterior lamellar stroma consists of a thick collagenous layer posterior to Bowman’s 
membrane. Collagen Type I and V are the predominant proteoglycans within the stroma 
and are composed of three polypeptide chains coiled in a triple helix. They polymerize to 
form elongated fibrils with diameters of 25–30 nm. Specific interaction between Type V 
collagen, located at the center of the fibril, and Type I collagen, on the exterior of the 
fibril and the relative ratio of Type V to Type I collagen helps in maintaining the 
uniformity of collagen fibril diameter. Additionally, the inter-fibrillar distance is highly 
uniform and is maintained by opposing interactions at the fibril surface.  
The lamellae form a hydrated matrix, which is rich in proteoglycans, glycoproteins, 
salts and keratocytes.  This pattern of lamellar organization and distribution is believed 
to control the corneal shape and curvature. Any change due to disease or injury that 
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disrupts this complex organization will cause loss of transparency, leading to scars and 
opacities that cause corneal blindness.  
The impact of corneal scarring to the patient is usually greater than scarring that occurs 
in other tissues since it has direct effect on vision. 
 
RESPONSE OF THE CORNEA TO INJURY (2) 
If the cornea sustains a superficial injury involving only the epithelium due to any 
cause such as trauma, infection or surgery, the stratified squamous epithelium covering 
the anterior surface of the cornea rapidly regenerates and healing occurs. This 
regeneration of corneal epithelial cells is mainly from stem cells. 
The Bowman’s layer, which is really a condensed part of the anterior-most layer of the 
stroma, serves as a barrier to the underlying stroma. However, if this layer is also 
damaged, it cannot regenerate; it is replaced by fibrous tissue. 
The same type of healing process occurs in the stroma.  
 
Stromal fibrosis  
Any alterations in the regular arrangement of collagen fibrils greater than a 20nm 
distance (one-half the wavelength of visible light) causes scattering of light which is seen 
by the observer as a stromal opacity (back scatter), whereas the patient experiences glare 
(forward scatter). The opacity can be in the form of a nebula (mild cloudiness-with clear 
visibility of iris), a macula (moderately dense spot-hazy iris details seen), or a leucoma ( 
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opaque, white opacity-iris details not seen). In general, the degree of corneal scarring is 
determined by the severity, duration and extent of healing. (2) 
The corneal scar pattern may have some characteristic features which may not be 
diagnostic but may give a clue regarding the diagnosis. Bacterial and fungal keratitis is 
usually associated with a focal, well demarcated scar whose depth reflects the level of 
penetration in the stroma. Vernal keratitis results in a discrete, shield-shaped anterior 
scar, generally in the superior part of the cornea. Syphilitic interstitial keratitis is 
associated with deep stromal scarring along with ghost vessels and lipid deposits.(2) 
 
The Descemet’s membrane is the basement membrane of the endothelial cell layer and 
can be regenerated by the endothelial cells to some extent when injured. The 
Descemet’s membrane is strong and generally resistant to corneal melting. During the 
progressive stage of corneal ulcers, when the rest of the affected corneal stroma has 
melted, this membrane forms a descemetocoele, which becomes the only barrier 
protecting the intraocular contents from infection.  
The corneal endothelium does not regenerate but if there is endothelial cells loss, the 
adjacent cells enlarge, change shape, and slide in to fill in the space. Thus the defects 
are closed, but the actual number of endothelial cells does not increase. 
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RISK FACTORS FOR INFECTIOUS KERATITIS  
In the normal eye, the intact corneal epithelium forms the main line of defense against 
microbes due to the presence of tight junctions (desmosomes and hemi desmosomes) 
between the epithelial cells. (3)Hence, a breech in the corneal epithelial integrity is 
usually present as a fore runner of  infectious keratitis. There are however, some 
organisms which can cause a corneal ulcer even in the presence of an intact corneal 
epithelium. Eg. Neisseria gonococci, Corynebacterium, Listeria etc. (4) (5)  
There are several other mechanisms which also serve to protect the ocular surface  
from infectious agents. The eyelids provide a physical barrier against direct access to 
the eye. The tears contain antimicrobial enzymes, complements like lysozyme, 
lactoferrin, betalysins and immunoglobulins that help ward off infections. The normal 
resident ocular flora also provides a balance thus preventing an overgrowth of any 
exogenous microorganisms. Additionally, the conjunctiva, which contains sub 
epithelial mucosa-associated lymphoid tissue and a collection of lymphoid cells, plays 
a role to protect the ocular surface.  
Other predisposing factors include lid abnormalities (eg. trichiasis, entropion, 
ectropion or lagophthalmos), tear-film abnormalities (eg. Sjögrens syndrome), 
exposure keratopathy, neuropathic keratopathy, ocular surface diseases (e.g., Stevens–
Johnson syndrome, chemical injury).  
Systemic conditions that may predispose to corneal infection are uncontrolled diabetes 
mellitus, chronic steroid use and systemic immunodeficiency. 
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Thus, any alteration of the local or systemic defense mechanisms predisposes the eye 
to microbial infection. 
Damage to the corneal tissue occurs due to the entry of organisms resulting in diffusion 
of toxins and enzymes. Polymorphonuclear leukocytes are recruited at the corneal wound 
site. Bacterial and neutrophil enzymes cause stromal damage which further facilitates  
bacterial invasion into the cornea which results in progressive tissue necrosis and 
sloughing of the epithelium and stroma.(3) 
Thus, several factors contribute to the damage caused by infectious organisms in the 
cornea. 
 
CORNEAL WOUND HEALING AND SCAR FORMATION 
The principle purpose of any wound healing response is to regain anatomical and 
functional capacity as fast and as perfectly as possible. 
The healing of corneal tissue is slower than in other connective tissues, possibly due to 
its complexity and avascularity. 
Corneal wound healing involves mechanisms that are complex and intricate. These 
include a cascade of cytokine-mediated interactions that occur between epithelial, 
stromal and endothelial cells, as well as corneal nerves, the lacrimal glands, the tear 
film and various cells of the immune system (6), (7).The activation of these 
mechanisms by organisms and the chemicals they elute, attracts immune cells, which 
are responsible for eliminating infective microbes that penetrate into the stroma as well 
as necrotic and cell debris (6). 
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MECHANISM OF CORNEAL WOUND HEALING 
Corneal wound healing is a complex process mediated by several cytokines, growth 
factors, and chemokines. These complex functions are modulated by epithelial cytokines, 
growth factors like IL-1, tumor necrosis factor-a (TNF-a), bone morphogenic proteins 2 
and 4 , epidermal growth factor (EGF), and PDGF, other inflammatory cells and  
keratocytes.The early phase of wound healing  involves degradation of damaged tissue by 
the plasminogen-activator/plasmin system, and metalloproteinases. Enhanced production 
of polymorphonuclear leukocytes in the corneal wound coincides with increase in matrix 
metalloproteinases (MMPs). In healing corneal wounds these collagenolytic enzymes 
(MMPs) are involved in the normal epithelial migration, initial stromal degradation and 
cleavage of collagen molecules during the inflammatory response. Following corneal 
wounding, expression of MMP-2 is increased and most of it appears in the active form. 
These changes persist for about 7 months, suggesting that MMP-2 is required for the 
prolonged process of collagen remodeling in the stroma. MMP-9 which is expressed in 
the epithelial layer is believed to be involved in  epithelial basement membrane 
degradation which precedes corneal ulceration, as well as  controls resynthesis of the 
basement membrane(8). It is possible that these proteolytic enzymes may play a role in 
the short-term and long-term stromal remodeling in the normal cornea. The MMP/tissue 
inhibitor of metalloproteinase (TIMP) systems may play an important role in the early 
stages of corneal wound healing as well as in scar formation.(3) 
 
Corneal epithelial wound healing 
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This can be divided into four phases with specific physiological functions (6) 
1. The latent phase:   
There is no cell movement nor is there a change in cell numbers. During this 
time there is increase in metabolic activity and a re-organization of the cell 
structure in preparation for the next phase.  
2. The migration phase: 
This phase is characterized by sliding over of the cells surrounding the wound 
resulting in coverage of the denuded surface.  
3. The proliferation phase: 
 The cells now begin to divide and differentiate in this phase, restoring the 
original structure and intercellular junctions of the epithelium.  
4. The final phase: 
During this phase the cell-substrate attachments (desmosomes/hemi 
desmosomes) present in non-motile epithelium begin to return. 
 
Stromal wound healing:  
 
There are three basic phases in stromal wound healing: (2) 
(1) Destructive phase: 
 Involves removal of diseased tissues by polymorphonuclear (PMN) 
leukocytes and macrophages, along with action of collagenases and 
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proteoglycanases from epithelial cells, fibroblasts, and other inflammatory 
cells. 
(2) Synthetic phase: 
 Involves synthesis of collagen and proteoglycans by stromal fibroblasts 
with the help of epithelial cells resulting in wound healing. 
(3) Remodeling phase: 
The newly synthesized materials are assembled into a scar tissue that is 
slowly remodeled into a clearer form resembling normal cornea but never 
achieving total transparency or normal strength.  
 
Endothelium and Descemet’s Membrane healing:  
Endothelial wound healing is limited to reorganization of the remaining cells and 
secretion of a new basement membrane. 
In mammals when tissue damage occurs, a fibrotic response is activated which usually 
heals the tissue, but in most cases fails to restore full function .(9)However, there are 
some instances such as during fetal wounding or in corneal epithelial wounds, that 
healing takes on a regenerative capacity wherein full function is restored.  
Corneal reaction to injury depends on the architecture and nature of the initial wound. 
(10)A theory of “activation” has been suggested by Fini et al. (9)where upon cells that 
undergo fibroblastic differentiation in response to injury will repair tissue by fibrosis, 
whereas cells that are able to proliferate in response to injury without activation will 
regenerate the damaged tissue. The subtle difference between the two modalities of 
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healing could be the difference between a resultant opaque tissue and a functioning 
transparent tissue. 
One of the most demanding challenges of corneal biology is to assist tissue repair via 
regeneration rather than fibrosis.  
Scar Formation 
 Although the cornea is considered to be highly resistant to immune response when 
compared to other tissues in the body, scarring of the cornea can develop due to many 
other reasons. (9) The extent of immune response and consequent permanent scarring 
is influenced by chemicals or debris that enter the eye, inflammations, corneal 
infections and inherent diseases of the cornea. Formation of scar tissue leads to 
changes in the optical properties of the cornea, which affects visual function. Injuries 
to the cornea can result in changes in the cell phenotype especially in the stromal layer. 
The tissue repair mechanism is initiated by disruption of Bowman’s layer as well as 
the Descemet’s membrane. This is followed by a fibrotic response which leads to rapid 
contraction and closure of the wound by activated keratocytes (fibroblasts). (56) 
However, this keratocyte activity is noted only after the corneal surface has fully re-
epithelialized. The fibrotic response in the cornea gives rise to an opaque scar, which 
interferes with vision. Furthermore, newly formed corneal scar tissue can never match 
the strength of uninjured tissue. 
The initial stages of wound healing elsewhere in the body involve removal of the 
injured tissue. This is then followed by cell proliferation and migration to the wound 
23 
 
site.  In the eye, repair and replacement occurs before the wound healing procedure has 
ended. (56) 
 
During the process of scar formation, a change in the collagen or the proteoglycan 
structure changes the highly organized lattice arrangement, compromising the optical 
properties of the cornea. Corneal scar tissue is less transparent, less elastic, and has 
lower mechanical properties as compared to a normal, healthy adult cornea(11). 
Increased cellularity of the scar, vacuolation and light scattering that occurs 
consequent to the modified sizes and arrangements of the collagen are all plausible 
explanations for these changes. 
 Electron microscope investigations on scarring reveal that new scars have vacuoles 
(vesicles found within the cytoplasm of cells) and collagen fibrils that are of a normal 
average diameter, but have a larger range of diameters. Improvement in corneal 
transparency over time may be due to the reduction of spacing between the fibrils 
which occurs with remodeling and approaches normal over time, although vacuoles 
remain. (11) 
Some investigators suggest that scar formation resembles fetal corneal synthesis in 
some mechanisms, in that the collagen fibrils secreted in the early stages are 
comparable in diameter to the parallel bundles of fibrils that are secreted during 
embryogenesis(11). Additionally, expression of fetal surface antigens for up to 6 
weeks following injury have been demonstrated in activated keratocytes. However, 
differences do exist; specifically, the reduction in the ratio of inter-fibrillar type VI 
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collagen to type I collagen in scar tissue as compared to the developing fetal cornea, 
and the lack of an organized template as is present in fetal tissue. (12) 
 
Management of infectious keratitis  
Prompt clinical and microbiological diagnosis is paramount for control of infection in 
infectious keratitis which along with appropriate management can reduce the incidence 
of severe vision loss and restrict corneal damage.  
Bacterial keratitis should be considered an ocular emergency as it progresses rapidly 
with disastrous complications. It is treated with empirical antibiotic therapy; one of two 
treatment options are typically employed: fluoroquinolone monotherapy, or a 
combination therapy consisting of fortified antibiotics (cefazolin 5% and tobramycin  or 
gentamicin 1.4%).  
The frequency of drops is dependent on the severity, but usually half to one hourly drops 
over 24 hours are used for most patients. A loading dose of antibiotic drop can be given 
every 5 min for the first 30 min in severe ulcers. The frequency of eyedrop instillation is 
tapered based on clinical response.(13) 
The aminoglycoside antibiotics, fortified gentamicin and tobramycin  provide  
excellent Gram- negative coverage and are also inhibitory against staphylococcus and 
some streptococcus but not against pneumococcus but are however epitheliotoxic. 
These antibiotics are fortified by adding 80 mg/2 ml of antibiotic injection to 5 ml of 
antibiotic eye drops (0.3%) to produce a concentration of 1.35%. Commonly used 
25 
 
cephalosporin in the fortified drops is cefazolin  and is prepared by mixing 5 ml of 
sterile water, to Injection Cefazolin 250 mg.(13) It has a good coverage for non-
penicillinase producing Gram-positive bacteria.  
The cornea being avascular, along with poor penetration of the drug into the stroma 
mandates frequent application of these topical antibiotics and is the basis for the 
concept of loading dose. It is important that minimum inhibitory concentration (MIC) 
of the drug is achieved at the site of infection. Concentration of the drug in the eye 
may be higher than the serum MIC levels which may explain a positive clinical 
response to an antibiotic to which the sensitivity in vitro was poor. In these conditions, 
a change in therapy is not required. Hence, clinical response to an antibiotic should be 
the first guideline of therapy. However, in a non-healing ulcer, in vitro sensitivity 
should also be considered. Additionally, before changing therapy, in vitro sensitivity 
must be correlated with in vivo response, as inadequate frequency of eye drops, poor 
stromal penetration, and necrotic debris can be the cause of decreased responsiveness 
to therapy. 
Signs of healing are:(13) 
1. Stabilization and no progression of lesion 
2. Decreased activity at infiltrate margin/blunting of ulcer edges 
3. Decrease in adjacent inflammation of the stromal reaction and anterior chamber 
inflammation. 
4. Progressive closing of epithelial defect with resolution of infiltrate. 
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In Fungal Keratitis , 5%Natamycin is the choice of treatment for filamentous fungal 
fungus (14). Surface debridement of the necrotic epithelium helps to reduce load of 
infection and better penetration of drugs. Drops are started as every half to one hourly 
initially and then tapered as per the clinical response. Response to treatment is very slow 
and complete resolution of the infection often may require prolonged treatment of 4-8 
weeks. 
Amphotericin B is considered effective against yeasts but not very effective against 
filamentous fungi; hence is the agent of choice against yeasts. Amphotericin B 
(0.15%) drops can be used alone or in combination with natamycin (5%) in refractory 
cases; however, they have poor penetration through an intact epithelium when 
compared to natamycin.  
Unlike in bacterial corneal ulcers, systemic treatment (Tab Ketoconazole) is useful in 
situations where fungus is suspected to have penetrated into the anterior chamber 
(endothelial plaque/cheesy hypopyon) as drug concentration in the anterior chamber is 
higher due to diffusion through the iris blood vessels. In these cases, intracameral 
instillation of amphotericin B(5-10 µg) has also been found to be useful in cases that 
are refractory to topical and oral antifungals.(15) 
The other group of antifungal drugs are azoles and fluocytosine which are generally 
employed as alternative agents for advanced ulcers or for ulcers refractory to polyenes. 
Oral Fluconazole has high corneal penetration and reaches adequate therapeutic levels 
in the cornea. It is useful against Candida and also to some extent against Aspergillus. 
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Patients, who have deep infiltrates, with inflammatory exudates in the anterior chamber, 
are often refractory to topical therapy. Oral medications like itraconazole 100 mg twice a 
day or ketoconazole 200 mg twice a day can be added in such cases. Broad spectrum 
azoles like Voriconazole has good intraocular penetration after oral administration.
 
and is 
a promising therapy for refractory fungal keratitis.(16) It is administered as oral 200 mg 
twice a day  and as drops (0.1-1%).(17) 
Newer agents available such as the triazole group (posaconazole and ravuconazole), 
echinocandins, nikkomycins may prove promising for the treatment of fungal keratitis in 
future. 
Acanthoemeba keratitis is a challenging entity to diagnose and treat. The most 
commonly used drugs include Chlorhexidine and polyhexamethylene biguanide (PHMB) 
against trophozoites and cysts.(18) 
 
 
ROLE OF STEROIDS IN INFECTIOUS KERATITIS – scar control 
The SCUT(Steroid for corneal ulcer treatment ) trial is the first largest, prospective 
randomized clinical trial done to assess the impact of topical corticosteroids in 
combination with antibiotics for the treatment of bacterial corneal ulcers.(19) 
Best corrected visual acuity (BCVA) was taken as the primary outcome in this trial since 
it is the most important, clinically relevant long-term outcome as compared to the 
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previous corneal ulcer studies which have focused on time to re-epithelialize, treatment 
failure, etc as outcome variables.  
The scarring that follows the resolution of infection is what results in visually impairment 
or blindness. The use of topical corticosteroids along with antibiotics to reduce immune-
mediated tissue damage and scarring has been advocated by some specialists.(20).  
In the SCUT trial, no significant difference in BCVA was observed in the 3-month follow 
up BSCVA (-0.009 [logMAR]; with a 95% CI, -0.085 to 0.068; P = 0.82) 
However, a significant difference in BCVA was observed in subgroups with baseline 
BSCVA of counting fingers or worse. These patients had 0.17 logMAR better visual 
acuity with corticosteroids (95% CI, -0.31 to -0.02; P = .03) compared with placebo at 3 
months, and patients with centrally located ulcers at baseline had 0.20 logMAR better 
visual acuity with corticosteroids (95% CI-0.37 to -0.04; P = .02).(19) 
 
Another prospective control study recruited a cohort of 50 SCUT participants at 4 years 
after enrollment to assess long term effect on visual acuity.(21)  
On average, vision improved by 2.9 logMAR lines from baseline to 3 weeks (P < 0.001), 
1.2 lines from 3 weeks to 3 months (P ¼ 0.002), and0.8 lines from 3 to 12 months (P ¼ 
0.01). The BCVA did not change significantly between 1 year and 4 years (0.04-line 
improvement, P ¼ 0.88). Also no significant difference was noted between the 
corticosteroid and placebo groups at the end of 4 years. 
Hence, it was concluded that cases of bacterial keratitis may continue to demonstrate 
improvements in visual acuity up to 12 months following diagnosis, but further 
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improvements are unlikely. These findings may guide the appropriate timing of surgical 
intervention in these patients.  
Our study intends to investigate exactly this; to assess the change in scar grade to 
clinically quantify improvement as well as to assess the subjective desire for corneal 
transplantation of the patients at the end of 1 year. 
No previous studies to the best of our knowledge, has attempted to quantify the change in 
corneal scar characteristics following infectious keratitis with functional assessment at 
the end of 1 year of follow up. 
 
EPIDEMIOLOGY  
Globally, 285 million people are visually impaired, of whom 39 million are blind.(22) 
According to the latest NPCB definition(23), about  20% of the global blind 
population resides in India; about 80 lakh patients(24). 
The definition of Blindness under the National Programme for Control of Blindness 
and Visual impairment (NPCB) is now modified and is in line with WHO Definition. 
Blindness is thus defined as presenting visually acuity less than 3/60(20/400) in the 
better eye and/or limitation of field of vision to less than 10 degrees from center 
of fixation (25). 
Corneal blindness, defined as blindness due to a corneal pathology, with potential 
visual recovery following a corneal transplantation, has been declared a major cause of 
blindness by the WHO. In developing countries, corneal opacity is a major cause of 
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blindness representing about 10% of blindness, following cataract(50%) and 
glaucoma(15%). (22) 
In India, the Andhra Pradesh Eye Disease Study (APEDS) revealed the prevalence of 
corneal blindness in at least one eye was 0.66% (95% confidence interval (CI) 0.49–
0.86). The most common causes for corneal blindness in this study included keratitis 
in childhood (36.7%), trauma (28.6%), and keratitis during adulthood (17.7%) (26). 
The major indication  of corneal transplantation in India is corneal scarring 
(28.1%) which includes post corneal ulcer scarring(12.2%), post-traumatic adherent 
leucoma(7.5%) and repeat grafts (for failed grafts)(17.1%). (28) 
In contrast, the major indication for corneal transplants in developed countries like 
USA, is Pseudophakic Bullous Keratopathy(27.2%) (29).
 
Most of the clinical studies  on corneal  ulcer  management  have focused  on healing 
time or cure  rates as  the  main outcome, where  success  is defined by the time taken 
for re-epithelialization.(28)   
A more  clinically  relevant  outcome indicator of success would  be  amount  of  
scarring  and residual  visual  acuity  following  healing  of  the  ulcer, which is a 
measure of  visual  disability and  is  also  relevant  to  the decision  regarding  corneal  
transplantation.  
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Final visual acuity following  an  episode of infective  keratitis is known to be  
affected by various  factors  including  size and  severity of the ulcer,  location and  
density of the scar.  
Visual disability however, would be  expected to  be influenced  by  factors  such  as  
vision  in the  un-affected fellow eye,  occupation,  as  well  as  co-morbid  conditions  
like  dry eye,  bullous keratopathy, lid deformities  and systemic conditions like 
Rheumatoid arthritis.(30)The nature of  the  infecting  organism, with specific 
reference to  unusual organisms  like  Moraxella  and  Serratia  are  also reported  to  
have  a  poorer  visual  outcome. (31)
 
The decision for a corneal transplantation in patients with  post-corneal  ulcer scarring 
is  usually  based  solely on  the visual acuity in  the affected  eye of the patient. 
However, the visual acuity as  recorded in a hospital  (with ideal  lighting  and a vision  
chart  that  provides 100% contrast),  may  give a  reading  that is  not a true measure 
of  the  patient’s  actual  visual function. Additionally, the patient may not experience a 
change, or may adapt remarkably well to reduced vision in one eye if the second eye is 
normal. 
To the best of  our  knowledge, there has been  no  study so far  that  has assessed  the 
visual   function(32)
 
 which  includes  binocular  visual  field (33),  stereopsis
 
(34),  
and  glare  acuity (35)
 
 along  with  visual acuity  in  a patient with  a corneal  scar  
following  a corneal ulcer.   
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With increased stress being placed on functional visual outcomes in current 
Ophthalmological practice, attention has been directed to the development and 
application of subjective visual function assessments using validated questionnaires. The 
success or failure of any medical or surgical interventions is assessed in units of “health-
related quality of life”, “functional outcome”, or “patient satisfaction”. “Quality of life” is 
a very vague, indistinct concept that is difficult to precisely measure and define. (36) 
Specialists involved in Visual Rehabilitation of patients rely on various different methods 
of functional assessment to serve as a surrogate for measuring Quality of Life. Although 
an objective measurement of visual impairment is important, this is not a sufficient 
assessment of a patient’s visual disability. Hence, a shift from purely objective visual 
assessments to subjective patient-based visual function assessments, using various types 
of questionnaires has come in vogue.(36) 
Some of the ancillary tests used in the assessment of other aspects of visual function are 
Visual field assessments, Stereopsis measurements and Glare Visual acuity.  
Visual Field Assessment 
Visual field testing is the only clinical test that assesses visual function beyond the 
macula. All the other visual function tests in a clinical setting concentrate on evaluating 
the central vision. Thus, visual field assessment gives information that does not overlap 
with other methods. Peripheral and central vision are essential for performing activities of 
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daily living, and people with significantly restricted field of vision experience many 
problems with regards to their occupational demands.  
Stereopsis Measurement 
The normal field of vision is composed of regions contributed to by both eyes. There is a 
substantial overlap between these regions since the eyes both face forward, but this is not 
complete in the temporal fields of each eye. The overlapping region is the binocular 
visual field and spans 110° in the central horizontal meridian.(37) The most important 
advantage of using both eyes is stereopsis. Stereopsis or true depth perception occurs 
because the two eyes do not get an identical image of the visual world due to their   
horizontal separation. The small differences in the images formed in the two eyes are 
related to the arrangement of points in depth, and provides information through the visual 
pathways to distinguish small changes in the distances at which objects lie in the field of 
vision. Stereopsis is most useful for making judgement of fine depth.   
 
Glare Acuity Assessment 
Strong and bright light sources like headlamps of vehicles coming from the opposite 
direction often create glare issues. Disability glare is the loss of contrast of retinal image due 
to intraocular light scattering caused due to irregularities in the optical media. 
(38)Additionally, exiting from a brightly lit area into a dimly lit room causes difficulty, as 
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a person has to adapt to the changing illumination conditions that is called adaptive 
glare.(38) Similar conditions are faced in certain occupations (e.g. night time driving, 
night shifts at construction sites where bright overhead lights are often used, computer 
professionals, etc.) These conditions, which are only mildly discomforting to most 
people, who can rapidly adjust to the condition, are disabling for those with eye problems 
like corneal scar, cataract etc.(37) 
Conditions of low luminance and glare can significantly increase visual disability and 
even produce impaired visual function in a patient whose vision may be otherwise 
normal under normal light conditions.  
 
Socio-Economic Status 
Socio economic  status (SES)  is  an  important  determinant  of  the  health,  
nutritional status,  mortality,  and morbidity  of  an individual. Socio-economic scales 
are an important part in the assessment of social status of an individual/family, which 
can have an effect on disease causing factors. It is also an important factor when 
considering providing health education to the target population. SES  also  influences  
the  accessibility, affordability,  acceptability,  and actual utilization  of  available  
health  facilities (39).  These social  factors  may  play a  significant  role  in  seeking  
treatment  for  the  visual disability caused  by  a  corneal  scar .(39) (40) Among the 
many Socio-economic scales devised, like Rahudkar scale 1960, Udai Parikh scale 
35 
 
1964, Jalota Scale 1970, Kulshrestha scale 1972, Kuppuswamy scale 1976, 
Shrivastava scale 1978 and Bharadwaj scale 2001, two scales particularly are very 
popular in India– Kuppuswamy (1976) and B G Prasad (1961) scales. Modified 
Kuppuswamy scale is commonly used to measure SES in  urban  communities. 
(41)The parameters used by this scale are education and occupation of the head of the 
family and monthly family income .(42) 
If, in addition to  the  above-mentioned  factors, the patient does  not  experience  a 
significant  visual  function  disability,  the  patient  may not  be adequately  motivated  
to go through  a  corneal  transplantation,  with  the long and  frequent  follow-up that  
this  entails.   
In addition, the success of corneal grafting in providing visual rehabilitation depends 
on a complex set of factors in a developing country and involves four major issues. 
Firstly, only well qualified corneal surgeons who are well equipped with facilities for 
surgery, follow up, and management of graft rejections and other postoperative 
complications, can successfully perform corneal transplantation.(43)  
Secondly, good selection of a candidate is vital as the outcome depends on the initial 
disease responsible for corneal blindness. Hospital based data on survival of corneal 
grafts done at a reputed eye institute in India showed that the 5 year survival rate of 
corneal grafts in that institution was 46.5% when performed for the first time for all 
causes leading to corneal blindness. Additionally, people belonging to a lower 
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socioeconomic status had 28% greater risk of failure of graft, and a 2.5 times risk of 
infection again causing graft failure (44)  
The third issue is the availability of enough number of good quality donor corneas for 
corneal transplantation from reliable eye bank facilities. The Eye Bank Association of 
India is a non-governmental organization which helps in increasing the collection, 
testing and distribution of good quality donor corneas, and setting standards of eye 
banking in India.(45) 
The fourth issue is the surgical expense of treating corneal blindness along with the 
long-term follow-ups required. These costs are generally higher than what is 
affordable by the population in a developing country. Most patients may require rigid 
contact lenses to attain full vision following a corneal transplant, which again raises 
the costs, and the potential for contact lens related complications. 
 
Moreover, they may not actually  need  a  corneal transplant  if  visual function as 
perceived by  the  patient (for  his/her  specific  lifestyle  and  occupation) is  not  
affected. 
This kind of data would be useful  in determining  the  actual need for allocation of  
corneal  grafts  which  are  in  short  supply, as  opposed  to the expected or predicted 
felt-need for corneal  transplant, based  on  the  prevalence of  corneal ulcers per  se  in 
the community. 
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METHODOLOGY 
STUDY DESIGN-    
 This was a hospital based observational study.   
The study design was a prospective study with 2 cohorts of patients, a 
retrospective/historical cohort, and a prospective cohort. 
SETTING- 
The study was conducted in the Department of Ophthalmology, Christian Medical 
College, Vellore which is a tertiary Eye Care Centre in South India. The total number of 
patients visiting the Ophthalmology department in a year is about 1.17 lakhs of which 
patients getting admitted with corneal ulcers is about 150-180 in a year. 
Prospective Arm: 
For the prospective arm, patients with infective keratitis followed up in our department 
and satisfying the inclusion and exclusion criteria were recruited after the ulcer healed 
(i.e. full closure of epithelial defect) from 1
st
 February 2016- 31
st
 July 2016. Data was 
collected regarding the history, microbiological diagnosis , treatment and socioeconomic 
status.  
A full ophthalmic evaluation including grading of the scar, visual acuity (LogMAR 
scale), binocular visual fields (Esterman score), stereopsis assessment (Lang Stereotest) 
and Glare Visual Acuity was performed. 
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Retrospective Arm 
For the retrospective arm, patients who were diagnosed with infective keratitis and had 
healed, and fulfilling the inclusion and exclusion criteria from 1
st
 February 2014 to 31
st
 
December 2015 were recruited. Data was collected from the available medical records, 
and the patients were contacted and invited for follow-ups at 1 year and/or at 2 years. 
PROSPECTIVE GROUP: 
Inclusion criteria: 
1. Patients who had 1st episode of infective keratitis were recruited after epithelial defect 
closure. 
2. Patients who were willing to come for follow-up as needed at our hospital 
 
Exclusion criteria: 
1. Perforated corneal ulcer at recruitment stage. 
2. Ulcers with viral etiology. 
3. Patients less than 18 years of age. 
4.  Previous ocular surgery (except cataract surgery). 
5. Other documented ocular diseases including retinal diseases, glaucoma, optic 
neuropathies, prior corneal scar and presence of Relative afferent papillary defect in the 
study eye. 
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RETROSPECTIVE ARM- 
Inclusion criteria:    
1. Patients who had a single episode of infective keratitis treated, healed and followed up in 
our hospital from 1st January 2014 – Dec 2015. 
 
2. The patients who were contactable and willing to come for follow up visits as required 
for the study. 
 
Exclusion Criteria:  
1. Perforated corneal ulcers. 
2. Ulcers with viral etiology. 
3. Therapeutic keratoplasty/other surgical treatment done for non-healing ulcers(except 
intracameral Amphotericin B) 
4. Patients less than 18 years of age. 
5. Previous ocular surgery (except cataract surgery). 
6. Other documented ocular diseases including retinal diseases, glaucoma, optic 
neuropathies, prior corneal scar and presence of Relative afferent papillary defect in the 
study eye.  
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PRIMARY OBJECTIVE- 
A. CHANGE IN CORNEAL SCAR GRADE 
A literature search did not reveal a specific post corneal ulcer scar grading. We therefore 
did a pilot study of 15 patients with a corneal scar, to decide on, and validate a clinically 
useful corneal scar grading, which is given below. It was devised combining location 
with respect to pupillary axis and density of the scars. 
 
The grading of the corneal scar was done at recruitment and at the follow up visits.  
For Location of the scar with respect to pupillary axis, distant direct ophthalmoscopy was 
used. 
Methods- 
• A direct ophthalmoscope was used with full illumination and large spot (aperture 
diameter) to illuminate both the pupils in a semi dark room. 
• The direct ophthalmoscope was held at 25cm from the patient, at the level of the 
eyes, close to the line of sight of the patient. 
• The scar location was graded as covering 0%, upto 25%, upto 50%, upto 99% and 
100% of pupillary axis. 
• The density of the scar was assessed using torch light examination. It was 
classified as follows- 
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- Nebula -A faint opacity with a clear view of iris details seen through the scar. 
-Macula - A more dense scar, with a hazy view of the iris details. 
-Leucoma - A dense, white opaque opacity with no view of iris details behind it. 
The grading was done as follows- 
Involvement of 
central visual axis 
NEBULA-A MACULA-B LEUCOMA-C 
1( 0% ) 1a 1b 1c 
2 (upto 25%) 2a 2b 2c 
3 (upto 50%) 3a 3b 3c 
4(upto 99%) 4a 4b 4c 
5 (100%) 5a 5b 5c 
 
SECONDARY OBJECTIVES- 
A. Visual Function: 
a. VISUAL ACUITY 
Visual acuity was scored with reference to the Logarithm of the Minimum Angle 
of Resolution (LogMAR). Each letter has a score value of 0.02 log units. Since there are 
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5 letters per line, the total score for a line on the LogMAR chart represents a change of 
0.1 log units. (ANNEXURE 6) The formula used in calculating the score is: 
LogMAR VA = 0.1 + LogMAR value of the best line read - 0.02 multiplied by (number 
of letters read) 
b. STEREOPSIS  
Stereo-acuity was measured using the Lang stereotest, consisting of random dots in 
certain shapes, which separates the view seen by each eye in these areas, similar to a 
hologram. In a person with no stereopsis, the image looks only like a field of random 
dots. The shapes are discernible in people with stereopsis. The different shapes are visible 
to differing extents depending on the level of stereopsis that the subject has.  Thus, with 
the lowest levels of stereopsis (gross stereopsis), only the figure of the cat is visible (1200 
seconds of arc). With better levels of stereopsis, the star is also visible. Subjects with very 
good levels of stereopsis are able to see all 3 figures, including the figure of the car (550 
secs of arc). (ANNEXURE 7) 
This test was used for the present study as it is a more sensitive and easily done test 
compared to the other tests like TNO, Random circle, etc.  It gives a general idea about 
the stereopsis of the patient .(46) 
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c. BINOCULAR VISUAL FIELD- Esterman Score 
Using HUMPFREY FIELD ANALYSER, under standard conditions  with the chin rest 
positioned in the midline, the binocular field was plotted with both eyes open and fixed 
on a central  target. The automated field analyzer recorded the outline of the binocular 
field on the special binocular chart. (ANNEXURE 7) 
The result of the functional visual efficiency of the entire peripheral field was expressed 
in percentage as the Esterman score.  A score of 85% or more represents a normal 
binocular field, and this score progressively reduces as the binocular field constricts. 
 
d. GLARE ACUITY 
Using the LogMAR visual acuity chart the patient was asked to read the vision chart with 
full refractive error correction.  Glare was then introduced with the help of a Brightness 
Acuity Tester (BAT).  The BAT consisted of a hemispheric bowl with a light located in 
its upper part, producing uniform illumination across the visual field.  The patients were 
asked to position the concavity of the bowl to their eyes and gaze through a 12-mm 
aperture in the center of the bowl with the contralateral eye occluded and to  read the 
same chart again. 
The medium setting of the BAT was used (400 foot Lamberts) to assess glare acuity and 
the values were represented in LOGMAR units.(ANNEXURE 8) 
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B. Subjective Perception Regarding Need for Corneal Transplantation 
At the last visit, each patient’s subjective perception for need of corneal transplantation 
following an episode of infective keratitis was obtained. A vision-specific quality of life 
questionnaire was given and detailed information about corneal transplantation was 
provided using a hand out with illustrations (ANNEXURE 5), if the patient was not 
aware of the procedure. 
Data was then collected and analyzed. 
 Algorithm of the study  
 
 
 
 
 
 
 
 
Retrospective Cohort: Patients 
with Infective keratitis  from the 
ulcer  ward register(1
st
  February  
2014 – 31
st
 December 2015) 
Prospective Cohort: All patients 
presenting to Septic ward from 1
st
 
February 2016 to 31
st
 July 2016 
Satisfaction of inclusion and 
exclusion criteria 
Satisfaction of inclusion and 
exclusion criteria 
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Data collected on pre developed 
proforma from medical records 
Patients were invited by calling up 
on telephone or by postcards for 
follow up 
Informed consent was obtained 
and complete eye examination 
Informed consent and recruitment 
after healing of ulcer 
 Complete Ocular examination was  
done by PI, and the predeveloped 
proforma was filled 
Corneal scar  grading, BCVA, Binocular visual 
field, glare  acuity, test for stereopsis were 
done at  3 month , 6 month, 1 year  follow up 
The above tests were repeated at each visit (3 
month, 6 month and 1 year and questionnaire 
regarding need for corneal transplant was given 
at the final visit 
Corneal scar grading, BCVA, 
Binocular visual field, glare 
acuity, test for stereopsis was 
done 
The above tests were repeated at 
each visit (1 year, 2 year); with a 
questionnaire regarding need for 
corneal transplant was given at the 
final visit. 
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SAMPLE SIZE 
There were no previous studies of this type found in our literature search. Hence, as this 
was an observational study, we decided to collect data on all patients presenting to our 
institution during the study period.  
STATISTICAL METHODS- 
Categorical data were expressed using frequency and percentages, and continuous data 
were expressed as mean (standard deviation-SD) or median (Interquartile Range-IQR) 
depending on normality.  
For the primary outcome change in corneal scar grade and also stereopsis, 1 year 
endpoint, 3rd and 6 month endpoint were considered. These grades between first time 
Data analysis and results 
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point and the end point were compared using Stuart Maxwell test (marginal symmetry 
test) as it has more than two categories for the categorical grades.  
The change over time for the variables Best corrected visual acuity, Esterman score, glare 
acuity were compared using repeated measures ANOVA and pot hoc comparisons were 
presented. 
All the analytical tests were performed using STATA I/C 13.1. 
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RESULTS 
A total of 71 eyes of 71 patients were included in the study, which includes 49 patients in 
the prospective arm and 22 in the retrospective arm at the start of the study.  
Prospective arm 
In the prospective arm 49 eligible patients were selected and then recruited at the time of 
healing (epithelial defect closure). These patients were followed up at 1 month, 3 months, 
6 months and 1 year.  
Only 22 patients completed all follow up visits until 1 year. 
2 patients were lost to follow up after the first visit itself.  
37 patients came for follow-up at 3 months. This number dropped to 24 patients at 6 
month follow-up, and 22 patients at 1 year follow-up. 
 
Retrospective arm 
In the retrospective arm, 60 patients were selected after going through the medical 
records. Eligible patients were contacted via telephone and postcards, but only 22 turned 
up. The reasons for the reduced numbers include wrong addresses and phone numbers, 
reluctance to hospital visits as they were symptom free, poor physical health, work 
commitments, financial issues and personal reasons. 
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Analysis for the demographics and questionnaire was done on the total number of 
subjects in the prospective and retrospective arms put together (n=71).  
The subjects in the prospective group were analyzed separately for the primary and 
secondary outcomes. 
               BASELINE CHARACTERISTICS OF STUDY PATIENTS 
Table 1: Overview of the baseline characteristics of all patients selected for this 
study. 
 
 
 
 
 
 
 
 
 
CHARACTERISTICS  
MALES 49.30% 
FEMALES 50.70% 
MEAN AGE(years) 49.89(+/-13.19) 
DURATION TO HEAL(weeks) 5.68(+/-4.97) 
BEST CORRECTED VISUAL 
ACUITY AT 
PRESENTATION(Mean 
LOGMAR) 
0.71 
CATARACT AT 
PRESENTATION 
22.54% 
PSEUDOPHAKES 5.63% 
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There were an almost equal numbers of male and female patients, and the mean age of 
recruitment was about 50 years of age. 
Of the total of 71 eyes, there were almost equal numbers of left and right eyes involved, 
i.e., 38(54.29%) were right eyes and 32(45.71%) were left eyes. The pie chart 
representing this is given below. 
FIGURE 1-Study eyes - 
 
 
Table 2 –Gender profile of the study patients- 
Males Females 
49.30% 50.70% 
 
The above table shows that there were almost equal number of females and males in the 
study. 
54.29%
45.71%
Right eye-54.29% Left eye-45.71%
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The mean age of the subjects was 49.89 +/-13.19 years. 
The mean duration to heal for the ulcer was 5.68 +/-4.97 weeks which was comparable 
to the results from unpublished data from our hospital. 
FIGURE 2-MICROBIOLOGICAL PROFILE OF THE ULCERS- 
 
 
The most common organism isolated after microbiological examination was fungus 
accounting for 47.89% of culture positive ulcers. This was followed by negative smear 
report (35.21%), whereas culture/smear positive bacterial ulcers was 4.23% as depicted in 
Figure 2. 
The fungus that was most commonly isolated was Fusarium (23.94%), and the most 
commonly isolated bacteria were Pneumococcus and Pseudomonas (1.41%). 
 
CULTURE
/SMEAR 
NEGATIV
E
35.21%
FUNGUS
47.89%
BACTERIA
4.23%
NOT 
SCRAPED
8.45%
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CORNEAL SCAR CHARACTERISTICS 
TABLE 3-DEPTH OF INFILTRATE 
 NUMBER PERCENTAGE 
<1/3
RD
 44 61.97% 
1/3-2/3
RD
 15 21.13% 
>2/3
RD
 11 15.49% 
FULL THICKNESS 1 1.41% 
 
Table 3 shows the depth of the ulcer at recruitment, which is correlated to the intensity of 
scarring after healing. The deeper infiltrates are expected to have a denser scarring 
compared to superficial infiltrates.  
TABLE 4- POSITION OF SCAR 
 NUMBER PERCENTAGE 
FULLY OCCLUDING 
PUPIL 
11 15.49% 
PARTIALLY 
OCCLUDING PUPIL 
40 56.24% 
NOT OCCLUDING PUPIL 20 28.17% 
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The above table depicts the position of the scar with respect to the pupillary axis / visual 
axis. The scars that are either partially or fully occluding the pupils will be more visually 
significant. 
PRESENCE OF CATARACT AT PRESENTATION AND FOLLOW UP VISITS 
(Prospective arm) 
FIGURE 3-Cataract at recruitment                  FIGURE 4-Cataract at 3 months 
                
 
 
 
 
 
NIL-65.31%
PRESENT-
18.36%
IOL-12.24%
NO VIEW-
4.08%
NIL-
52.78%
PRESENT-
25%
PSEUDOP
HAKIC-
16.67%
NO VIEW-
5.56%
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FIGURE 5-  Cataract at 6 months        FIGURE 6-Cataract at 1 year 
   
The above figures show how the percentage of subjects with cataract increased from 
recruitment to the 1 year follow-up visit. This may be explained due to the associated 
inflammation which may persist for some time even after the epithelial defect has healed. 
SOCIAL FACTORS- 
The majority of the study population belonged to the low socioeconomic strata as shown 
in the following table. 
 
 
 
 
 
NIL-52.17%
PRESENT-
34.79%
PSEUDOPHA
KIA-4.35%
NO VIEW-
8.7%
NIL-45.45%
PRESENT-
27.28%%
PSEUDOPHA
KIA-22.73%
NO VIEW-
4.55%
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TABLE 5 - Socio Economic Strata (SES)  
SES SCORE PERCENTAGE OF PATIENTS 
<5 4.23% 
5 - 10  77.46% 
11 – 15 14.08% 
16 -25 2.82% 
26 -29 1.41% 
 
The majority of the population was agriculturists followed by manual labourers. 
TREATMENT VARIABLES- 
Since the majority of isolates were fungi, maximum number of patients in the study were 
treated with Natamycin (60.56%) followed by the others. 
Topical steroids were used in 15.49% of the subjects in culture positive Pseudomonas 
and Pneumococcal infections after the sensitivity report was obtained. 
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PROSPECTIVE ARM  
PRIMARY OUTCOME RESULTS:  
Corneal Scar Evolution Evaluation 
The primary outcome included change in corneal scar grading from the time of healing               
(at recruitment) upto 1 year. The scar grades were divided into 3 groups based on their 
density for the purpose of analysis. All the patients irrespective of the site of scar, were 
divided into group A-Nebula, group B-Macula and group C-Leucoma, as the location of 
scar remained the same, and the change in grade was observed over 3 months, 6 months 
and 1 year. 
TABLE 6 -The following Contingency Table shows change in scar grade from the 
time of recruitment to 1 year- 
 
SCAR  
GRADE 
AT  
THE  
TIME  
OF 
RECRUIT
MENT 
                SCAR GRADE AT THE 1 YEAR FOLLOW UP 
 NEBULA(a) MACULA(b) LEUCOMA(c) Tota
l 
NEBULA(A) 1(100%) 0 0 1 
MACULA(B) 9(60%) 5(33.33%) 1(6.67%) 15 
LEUCOMA(C) 2(33.33%) 1(16.67%) 3(50%) 6 
Total 12(54.55%) 6(27.27%) 4(18.18%) 22 
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It was found that in Group A, only 1 patient was present and no change in scar grade was 
noted over 1 year.  
However, out of the 15 people in Group B (Macular scar), 9 patients (60%) were found to 
have an improvement in the scar grade to Leucomatous scar and so shifted to group A, 
whereas 5 patients (33.33%) had remained the same, and 1 patient had worsened to group 
C. 
Out of the 6 patients in Group C (Leucomatous scar), two (33.33%) patients had 
improved to group A, one (16.67%) patient improved to group B and 3 patients had no 
change(50%). 
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FIGURE 6: GRAPH DEPICTING PERCENTAGE OF PATIENTS IN EACH OF 
THE SCAR GROUPS AT DIFFERENT POINTS IN THE STUDY 
 
 
Figure 6 clearly depicts that the numbers of patients with Nebula grade scars has 
increased over one year, while those with Macula and Leucoma grade scars has decreased 
from presentation to the 1 year follow up visit. 
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              TABLE 7 - Change in scar grade over 1 year (statistical significance) 
Change In scar Grade  P value 
From time of recruitment follow up at 3 months 0.61 
From 3
rd
 month to 6
th
 month 0.37 
From 6
th
 month to 1 year 0.13 
From time of recruitment to follow up at 1 year 0.003 
 
The change in grade of scar (improvement in the grade of scar) at 1 year was 
highly statistically significant: P value 0.003. 
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THE SECONDARY OUTCOME RESULTS:  
1. Best Corrected Visual Acuity (BCVA) 
TABLE 8 - Change in BCVA (in LogMAR units) from baseline (at the 
time of recruitment), at 3 months, at 6 months and at 1 year. 
Time          n MEAN 
LogMAR 
STANDARD 
DEVIATION 
Baseline (at 
the time of 
recruitment) 
49 0.71 1.69 
3 months 37 0.76 1.95 
6 months 24 1.00 2.50 
1 year 22 0.48 0.46 
 
The above table shows that the Mean LogMAR Visual acuity had slightly 
decreased from the time of healing (0.78), at 3 month(0.76) and 6 month 
(1.00)follow up visits, but improved at the final 1 year visit(0.48). 
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TABLE 9-PAIRWISE COMPARISON OF PREDICTIVE 
MARGINS(BCVA) 
 3month vs 
baseline 
6month vs 
baseline 
1year 
vs 
baseline 
6 month 
vs 3 
month 
1 year vs 
3 month 
1 year vs 
6 month 
P 
VALUE  
0.507 0.213 0.000 0.505 0.003 0.049 
95% CI -0.771 to 
0.038 
-116 to -
0.264 
-0.201 
to -0.63 
-0.102 
to-0.050 
-0.186 to  
-0.040 
-0.174 to 
-0.005 
 
The above table shows that best corrected visual acuity has improved at the 1 
year visit (P value - 0.00) when compared to the baseline which is the time of 
healing. 
 
 
 
 
 
 
63 
 
2. Binocular Visual Field - Esterman Score 
TABLE 10 - Change in Esterman score (0-100) signifying binocular visual 
field from baseline at the time of scarring, at 3 months, at 6 months and at 
1 year. 
ESTERMAN SCORE n MEAN STANDARD 
DEVIATION 
Baseline(at the time of 
recruitment) 
48 91.67 18.91 
3 months 36 96.92 7.48 
6 months 21 95.86 7.91 
1 year 22 96.09 6.65 
 
The above table shows that the Binocular visual field as measured by Esterman 
score has improved from the time of recruitment to the 3
rd
 month visit and 
remained more or less the same in the further visits. 
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FIGURE 7-Mean and confidence interval graphs of Esterman score over 1 
year. 
 
TABLE 11 - PAIRWISE COMPARISON OF PREDICTIVE MARGINS 
(Esterman score) 
 3month vs 
baseline 
6month 
vs 
baseline 
1 yr vs 
baseline 
6 month 
vs 3 
month 
1 yr vs 3 
month 
1 year vs 
6 month 
P 
VALUE  
0.162 0.163 0.0016 0.793 0.223 0.421 
95% CI -1.298 to 
7.619 
-1.634 to 
-9.515 
1.305 to-
12.242 
-5.132 to 
-6.692 
-2.242 to -
9.469 
-4.135 to 
9.801 
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Esterman binocular visual field score did not show any statistically significant 
change over 3 months (P value-0.162), 6 months (P value-0.163) but showed 
improvement over 1 year visit (P value-0.001) compared to time of healing. 
3. Glare Acuity 
   TABLE 12 - Change in glare acuity (in LogMAR units) from baseline at the time   
of  recruitment, at 3 months, at 6 months and at 1 year.   
GLARE ACUITY  n MEAN STANDARD 
DEVIATION 
Baseline(at the time 
of recruitment) 
48 0.56 0.46 
3 months 36 0.52 0.50 
6 months 22 0.44 0.44 
1 year 23 0.58 0.58 
               
               The above table shows that the mean glare acuity has improved marginally from 
the time of recruitment over 3 and 6 months but shows a small decline at 1 year. 
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 FIGURE 8-Mean and Confidence Interval graph of glare acuity (LogMAR) over 1 
year. 
 
 
TABLE 13 -PAIRWISE COMPARISON OF PREDICTIVE MARGINS 
(Glare acuity) 
 3month vs 
baseline 
6month vs 
baseline 
1 yr vs 
baseline 
6 month 
vs 3 
month 
1 yr vs 3 
month 
1 year vs 
6 month 
P 
VALUE  
0.128 0.028 0.006 0.364 0.145 0.653 
95% CI -0.131 to 
0.016 
-193 to         
-0.011 
-0.216 to 
-0.382 
-0.142 to 
0.052 
-0.164 to 
to 0.024 
-0.136 to 
0.086 
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There was no significant difference at the 3
rd
 month (P value-0.162) and 6
th
 
month visit(P value-0.163), but at 1 year visit statistically significant  decline 
in glare acuity was noticed(P value-0.006) compared to time of recruitment. 
This may be attributed to the increase in cataract noted in these patients over 1 
year. 
4.  Stereopsis – Lang Stereotest 
TABLE 14 - Change in stereopsis -from the time of recruitment to the 
endpoint (at 3 months, at 6 months and at 1 year) 
 
Grade of 
stereopsis 
At the time of 
recruitment 
At the final 
visit 
ST Grade, n(%) 
550 33 (67.3) 30 (63.83) 
600 4 (8.2) 4 (8.5) 
1200 1 (2.0) 2 (4.3) 
<1200 11 (22.4) 11 (23.4) 
 
Normal stereopsis according to a Korean study, for the age group 41 to 50  
ranged from 37.5 (±20.7) to 110 (±42.4),) based on different stereotests 
(47).Stereopsis was decreased at all visits including at recruitment.  
It was found to be 550 seconds of arc in 67.3% and below 1200 seconds of arc 
in 22.4% by the Lang I stereotest which is low for the age. There was no 
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significant change in stereopsis in all the 4 groups from the time of recruitment 
to the 1 year visit. 
RETROSPECTIVE ARM 
           TABLE 15: Mean and Standard Deviation Table of the Secondary   
            Outcomes (Retrospective Arm) 
 Best corrected 
visual acuity  
Esterman score Glare acuity 
 1 year  2 years 1 year 2 years 1 year  2years 
n 10 9 13 9 11 8 
MEAN 0.28 0.37 88.46 85.67 0.31 0.45 
STANDARD 
DEVIATION 
0.22 0.33 14.07 32.57 0.28 0.29 
The above table shows that there was no significant change in visual acuity, 
glare acuity and binocular visual fields over 2 years in the retrospective arm. 
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FIGURE 9: Mean and confidence interval graphs of Best corrected Visual 
acuity in the retrospective arm 
 
 
 
FIGURE 10: Mean and confidence interval graphs of Esterman score in 
the retrospective arm 
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FIGURE 11: Mean and confidence interval graphs of Glare acuity in the 
retrospective arm 
 
 
SUBJECTIVE PERCEPTION REGARDING NEED FOR CORNEAL 
TRANSPLANTATION (at the final follow up of both retrospective and prospective 
study groups)  
VISION: 
1. WAS THE VISION NORMAL PRIOR TO THE ULCER? 
FIGURE 12: VISION NORMAL PRIOR TO THE ULCER 
 
YES-98.53%
NO-1.41%
71 
 
The above figure shows the most of the patients felt they had normal vision prior to the 
ulcer. 
2. THE ACTIVITIES RESTRICTED AFTER THE ULCER 
FIGURE 13: RESTRICTION OF ACTIVITY 
 
The above table shows that most of the patients did not experience any restriction in their 
activities due to the ulcer. 
SPECTACLE USE 
FIGURE 14 -USE OF SPECTACLES 
 
NO CHANGE-
80.30%
ADL+few
activities-9.09%
ADL-7.58%
SPECTACLE USE
YES-15.87%
NO-84.13%
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84.13 % of the subjects did not use spectacles. 
TYPE OF SPECTACLES 
        TABLE 15 - TYPE OF SPECTACLES 
PRESCRIPTION 80% 
PLANO NON TINTED 10% 
DARK GLASSES 10% 
Most of the patients used prescription glasses and only 10% uses dark glasses. 
REASON FOR USING SPECTACLES- 
FIGURE 16-REASON TO USE SPECTACLES 
 
Only 10% of patients used glasses to reduce glare whereas most of them used it for 
improvement in vision. 
 
 
REASON FOR SPECTACLE USE
BETTER VISION-80%
REDUCE GLARE-10%
ADVISED TO USE-
10%
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CORNEAL TRANSPLANTATION 
1. PERCENTAGE OF PATIENTS WITH AWARENESS ABOUT 
CORNEAL TRANSPLANTATION 
                FIGURE 17-Awareness about corneal transplantation 
 
More than half of the patients did not have any awareness about corneal 
transplantation. 
 
 
 
 
 
 
YES-36.23%
NO-63.77%
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2. PERCENTAGE OF PEOPLE WHO FELT THAT THEY NEED 
CORNEAL TRANSPLANTATION 
FIGURE 18-Subjective need for corneal transplantation. 
 
After educating the patients who were not aware of corneal transplantation, 
they were asked whether they feel they need to undergo the procedure. Only 
5.88% felt that they needed corneal transplantation. 
3. All the subjects (100%) in the study who felt that they need corneal 
transplantation felt it was for improvement in vision, rather than any other 
reason (cosmetic, etc.) 
 
 
 
YES-5.88%
NO-94.12%
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4. The main reason for denial of corneal transplantation was the subjective 
feeling that there was no visual defect precluding normal activity at the end of 
1 year (83.08%). 
FIGURE 19 - Reason for denial of corneal transplantation 
 
 
The main reason for denying the need for corneal transplantation among the patients was 
absence of any visual defect. 
 
 
 
 
 
Financial
constraints-7.69%
No visual defect-
83.08%
Follow up not
possible-1.54%
Follow up not
possible-7.69%
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DISCUSSION 
 
Corneal blindness, defined as blindness due to a corneal pathology, is a major cause of 
blindness in the developing world. The burden of corneal blindness on an individual and 
the wider community can be huge, particularly as it affects people at a younger age 
compared to other causes of blindness like cataract and glaucoma. It’s also unevenly seen 
more in the poor rural population, because of the increased risk of eye trauma from 
contaminated objects such as plant material, limited access to treatment and low 
socioeconomic status. 
As reported in the Andhra Pradesh Eye Disease Study (APEDS), the major cause of 
corneal blindness in a rural south Indian population was scarring due to trauma, and 
keratitis in childhood and were responsible for a significant proportion of corneal 
blindness across all age groups. Keratitis and corneal scar post cataract surgery were 
important causes of corneal blindness for those 50 years of age or more. The chances of 
suffering from corneal blindness increases with age, and is also higher for those 
belonging to the extreme lower socioeconomic status .(27) 
This study was done on 71 eyes of 71 patients of which 49 patients belonged to the 
prospective arm and 22 patients in the retrospective arm. 
In our study, the mean age of the population affected by keratitis and post keratitis 
scarring was 48.49 years in the prospective arm and 53 years in the retrospective arms 
which is in comparison with the Andhra Pradesh Eye Disease Study, if patients under 15 
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years are excluded. (48)There were almost equal numbers of males and females in this 
(Males 49.3% vs Females 50.7%). (TABLE 2) In most rural settings, both the males and 
females are equally involved in agricultural labor. 
The mean duration to heal for all the ulcers in this study was 5.68 weeks. This is almost 
exactly the same as that found in another study done in our institution (unpublished data) 
5 years ago.  
The most common organism isolated was fungus(47.89%), predominantly 
Fusarium(23.94%) which is similar to the microbiological profiles in other similar studies 
done in South Indian population.(49) (50).(FIGURE 2) 
As is evidenced in various studies (51) which compared the socioeconomic status and 
predisposition to infective keratitis, this study also shows a similar pattern. In the present 
study 81.7% of cases of microbial keratitis belonged to lower socioeconomic group with 
the socioeconomic score less than 10 (according to Modified Kuppuswamy grading). 
(TABLE 5)  
Patients belonging to lower socioeconomic groups have more occupation-related trauma 
with vegetative matter, poor ocular hygiene and awareness, compromised nutritional 
status and less affordability and accessibility to medical aids.  
CHANGE IN CORNEAL SCAR GRADING 
The primary outcome of the present study was based on change in corneal scar grading 
after healing of an episode of infective keratitis. A clinically relevant scar grading was 
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devised based on the combination of location with respect to pupillary axis and the 
density of the scars. The grading of the corneal scar was done at recruitment and at the 
follow up visits. For the ease of analysis the 15 grades as discussed in the methodology 
section (Appendix 11) were divided into 3 groups A, B, C. 
Although the size of the corneal scars in these subjects generally did not change between 
the 3- and 12-month visits, there was a statistically significant reduction in the scar 
grading, becoming LESS dense at the one-year follow-up visit. (P-0.003). (FIGURE 6, 
TABLE 7) 
This statistically significant improvement in the scar grading was also reflected in the 
visual acuity improvements at the one-year follow up as the results of our secondary 
outcomes show.  
 
The secondary outcomes we studied included change in Best Corrected Visual Acuity 
(BCVA), binocular Visual field, glare Acuity and stereopsis. 
BCVA was found to have improved with a statistically significance at the 1 year visit of 
P = 0.000) when compared to baseline and also when compared to the 3
rd
 month visit (P 
value-0.003) (Table 9). 
These results are consistent with the case series  published from the data of The Steroid 
for Corneal Ulcer Trial (SCUT) where large central scars following bacterial keratitis 
showed considerable decrease in the density of the opacity, even between the 3
rd
 month 
and 1 year. It was also attributed to the central scars from bacterial keratitis having lesser 
irregular astigmatism at 1 year compared with 3 months. (52) 
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In our study, the visual acuity showed a decline in the 3
rd
 month and 6
th
 month visit. 
(Table 8) with an improvement occurring again by the one-year follow-up. This 
improvement in vision can be explained by the process of scar remodeling that occurs 
during corneal wound healing which can take up to one year. 
The percentage of people who underwent cataract surgery also increased to 22.73% at 1 
year compared to the 4.35% at 6
th
 month visit (Figure 5 & 6). 
 
The binocular visual fields were assessed using the Esterman field which is an objective 
measurement was obtained using the Esterman score(ranging from 0-100).(33)(53) The 
Esterman binocular visual field score did not show any statistically significant change 
over 3 months(P value-0.67), 6 months(P value-0.21) but showed improvement over 1 
year visit(P value-0.00) compared to baseline.(Table 11). This anecdotal improvement in 
binocular field of the patients can be attributed to the improvement in density of scar.  
 
Glare visual acuity is another functionally important variable to assess patients with 
corneal scar. Logmar Visual acuity using the Brightness Acuity Tester (BAT) is 
illustrated in Table 12 and 13.  
Our study revealed a marginal improvement in glare acuity for the first 6 months post 
recruitment, but a statistically significant decrease in glare acuity at the one year visit 
compared to the baseline glare acuity. 
This may be due to the development or worsening of cataract over the course of 1 year, 
which was demonstrated in this study.  
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Stereopsis- 
The stereopsis measured at baseline was significantly lower than for a normal population. 
Thereafter, no significant change in stereopsis was noted from baseline at the time of 
scarring to the endpoint (at 3 months, at 6 months and at 1 year). (Table 14) 
This means that even with all the scar remodeling that occurred over one year, quality of 
vision did not improve significantly enough to improve binocularity at one year following 
closure of epithelial defect. 
 
SUBJECTIVE PERCEPTION OF NEED FOR CORNEAL TRANSPLANT 
A vision-specific Quality of Life and corneal transplantation related questionnaire was 
administered to both the Prospective cohort of patients (at the end of 1 year), and the 
Retrospective cohort of patients seen at the end of 1 and/or 2 years. 
 This questionnaire is different from the VF-14 questionnaire which is commonly used 
in studies to assess visual function and has driving related parameters.(54) (55) 
The questions asked in this study cater to a population with a low socioeconomic 
background for whom VF-14 may not be suitable.  
Almost all the patients from both the cohorts reported normal levels of vision in the 
affected eye before the onset of the corneal ulcer. (Figure 12). 
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At one year following the healing of the ulcer, nearly three quarters of the patients 
reported no limitation in Activities of Daily Living (84.09%; prospective cohort: 
72.73%; retrospective cohort). (Figure 18) Most of the subjects did not use glasses 
routinely, and among the ones who used, 80% of patients used prescription glasses 
(power for both eyes) for better vision (Figure 16 & Table 15).  
When asked regarding knowledge related to corneal transplantation, slightly more than 
half of the patients (63.77%) did not have adequate knowledge. (Figure17) This is a 
problem that needs to be countered by educating all patients about the future 
possibilities for visual rehabilitation following healing of their corneal ulcer. 
These people were then given handouts with pictures describing the procedure and 
then questioned as to whether they felt the need for corneal transplantation. 
94.12% of the patients felt that they do not need corneal transplantation (Figure18). 
The main reason they gave was that they did not perceive a visual defect significant 
enough to warrant undergoing corneal transplantation (83.08%) (FIGURE 19).This 
finding is hugely significant, as it presents another perspective to the use of corneal 
donor tissue. Just because a patient has had a corneal ulcer, does not mean that they are 
automatically placed in the corneal transplant waiting list.  
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CONCLUSIONS 
This study is the first prospective report on the continual change in corneal scar grading 
over a follow up of 1 year after healing of an episode of infectious keratitis. Similar 
studies examining outcomes following infectious keratitis have mainly used vision, rather 
than corneal scar grading as their primary end point.  
The present study mainly concentrated on determining the change in scar grade along 
with other visual function variables and a vision-specific Quality of Life questionnaire. 
The following are the conclusions from this study: 
1. The corneal scar grade reduces significantly at one year following healing of the 
ulcer (p=0.003) 
2. Binocular Corrected Visual Acuity improves significantly at one year following 
healing of the ulcer (p= 0.000) 
3. Glare acuity reduces slightly at the end of one year following healing of the ulcer 
(p=0.006) 
4. Esterman binocular visual field score did not show any statistically significant 
change over 3 months and 6 months but showed slight improvement over 1 year 
visit(P value-0.001) 
5. Stereopsis is reduced when a corneal ulcer occurs, and remains unchanged at one 
year following healing of the ulcer. 
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6. More than 93% of patients did not feel the need for a corneal transplant following 
the corneal ulcer, the main reason (>75%) being absence of perception of a visual 
defect significant enough to warrant undergoing corneal transplantation 
 
The results of the present study proves that a combination of all the visual outcome 
variables used, and not just visual acuity would be a  better  determinant of the outcome 
following corneal ulcer.  
It is important to establish an information channel explaining all future possibilities for 
visual rehabilitation including the option corneal transplantation, with all its pros and 
cons to all patients who have had a corneal ulcer. The survival of a corneal graft would 
be better assured if the recipient is a motivated patient, knowledgeable about the 
benefits and problems of corneal transplantation, and feels the need to undergo this 
procedure. Hence, corneal transplantation could be delayed in patients with good 
contralateral vision so that the corneal grafts, which are in short supply, are allocated 
to the deserving patient. 
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LIMITATIONS 
1. The main limitation in the study was the large numbers of drop outs at the 1 year 
follow up as compared to the start of study.  
2. The final vision measured was a Best Corrected Visual Acuity using spectacles; a 
Rigid Contact Lens trial could have provided a better subjective and objective 
improvement in vision. 
3. Cataract could have been a confounder for BCVA measurements, especially in those 
patients with cataract who had not undergone cataract surgery before the last visit. 
4. Apart from glare acuity and stereopsis, measurement of contrast sensitivity could also 
have been a useful variable which influenced the visual function. 
5. The questionnaire which was asked at the end of the study would have been more 
relevant if was asked at the start of the study also as it would have provided a 
comparison. 
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2. Copy of clinical research form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. No: Hosp I\o: Age: Scx: IVI | trt'
Study Eye: R / L DO presentation: Duration to Healing:
Size: Vertical- Horizontal-
Depttr of infiltrate: <113 | 113-Zl3 / >213 lPosterior half only/ Full thickness
Thinnin g: <25Ya | 25-50% I >sAoh / Descometocoele
Position : Fully occluding pupil I Partially occluding pupil / Peripheral
Glue: Yes / No
Cataract: Nil / Present I Developed during Rx / IOL i Aphakia
Fundus vielv: Clear/ Vessels seen/onlv clisc seen / No vier,v
F undus lmpression: Normal / Abnorrnal If abnormal, lesion
f--linical Imp: Bacterial / Fungal
Systemic illness: DM /Autoimmune / Dry Eye
MICRO:
$jmear: Negative / Fungus /Gram *ve cocci /Gram -ve bacilli /Others.
Species: No growth
llacteria: Pseudomonas / Pneumococci / Nocardia I others,
Fungus: Aspergillus / Fusarium I Curcularia llLaciodiploidea / others
SOCIAL FACTORS-
Education- Literateiilliter"ate
Area- Rural/ Urban
t;
Occupation-
SlrS Score-
Ho usewitel Unemployed/ A griculturer/L,abou'e l'l
Clerk/Professional
26-29 I 16-25 I 1 1 - 1 5/5- t 0/<5
TREATMBNT:
Medical:
Antibiotics: CP I F. Genta / Cefazolin / Norflox / Chloro / Septran
Others.
Antiftrngal: Natamycin / Kel.oconazole / Itraconazale / Ampho I
Others.
Steroids: No 1 Yes Duration.....
Surgical:
Inl.ra carneral Anrphotericin /'farsoraphy / Glue / Others
OBJECTIVB FINDINGS:
Scar grading:
Inva
99_
r(
2(
3 (upto 5A%)
4(upto 99%)
s {r00%)
*ht^r"t 
"J'ntral visual uxis
NEBULA-a MACULA-b LEUCOMA-c
0%\ 1a 1b 1c
upto 25%) 2a 2b 2c
o 3a 3b 3c
ot  4a 4b 4c
IA0 5a 5b 5c
SC-\R GRADL.
CATARACT
GR,t\Dl:
tPSC/NS grade)
ESTERMAN
scoRE(%)
G[-ARE
AC tJ I ' f  Y-in
togMAR
(rN'f ENSI',fY-
100 fbot
lanibert)
STEREOPSIS
i 200/600/5 50
(seconds of
arc)
Pin hole vision (t inal) :
lX. \ 'A ( I i inal) :  Study Eye:
o R.efrnction:
Fellow Eve:
F'untlus view nt last visit: CllcariVessels seen/cnly clisc seen/nct vielv
StJ t].lECT'IVhl P Ii RC Ii I'TION :
Vision i
Was vision norntal before? Ycs/No
Wlrat actir.ities have Lreen restricted lbllor.ving the ulcer'/ o 
.
No chanse / i\Dl-r-a f-ew otlrers / ADL /not able to clo anything
( ADL-activit ies ot' daily l iving)
Spectaclcs:
llo you Lrse spcctarclcs'? Ye:; I No
'l-ype'l PrescriptionlPlano non tinted/ Dark glasses
Wly'l Better vision/ Reducc glarelTo hide the eye/ Told to do so/ others
Cornetl'f r:rnsplit t tittion :
Do vou know ithout Corneal transplantation? Yes / no
it..; you think yort need cortreatl ' fransplantion'/ Yes / ' ' :c
lf 1,ou 1cet1. wliy'/ Vision/ Cclsmesis/ fJecause it is arvailable/ Others
Il'ypu c]o not \\.ant. lvhy'l No time/ Financial constraints/ i'Jo visuai defbctl
Follow up not possible
I.,lotes
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3. PARTICIPANT INFORMATION SHEET  
Change in corneal scar characteristics and visual outcome in patients with healed 
infective keratitis 
Name of participant- 
Study no- 
Principal Investigator – Dr. Sherina Thomas 
Research Site –      Schell Eye Hospital 
                                Christian Medical College, Vellore 
                                Tamil Nadu, India 
You are invited to take part in this study. But, before you decide whether or not to 
participate in this study, it is important for you to understand why the research is being 
done and what it will involve. The information in this document is meant to help you in 
the same.  
1. What is the purpose of this study? 
We are doing a study to evaluate the change in scar features and factors affecting vision 
in eye infections like yours. Infective corneal ulcers are a major cause of ocular morbidity 
in our country. Most corneal ulcers with rational and adequate treatment heal, but with 
different degrees of residual corneal scarring. We are trying to study the conditions that 
affect the final visual outcome of such eye infections which can help in making decisions 
regarding patient management and rehabilitation in future 
2. If you take part, what will you have to do?  
The duration of this study is 12 months.If you agree to participate in this study; we will 
take the details of your clinical examination, surgical intervention and treatment in the 
ward along with a questionnaire. Following discharge, you will need to come for 3 
monthly, 6 monthly, 1 yearly follow up. During the follow up, you will meet me 
Dr.Sherina Thomas, who is the primary investigator of the study 
3. Are there any risks for you if you take part in this study? 
  Apart from the extra time that is needed to do the tests and to record all your details (this 
might be as long as 30minutes), there is no other risk or inconvenience anticipated by 
your being part of this study.  
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4. What are the benefits if you take part in this study? 
 The benefit that you may gain out of the study is that you get a detailed evaluation for 
your scar and visual disability and it will help decide on further treatment like corneal 
transplantation. 
   
5. Do you have to pay? 
You will have to pay only for the tests that are required for the routine management of 
your disease. All additional investigations for the study will be done free of cost. 
Participants will not be paid for their involvement. 
5. What if I don’t want to take part in this study or if I want to withdraw later? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your 
usual treatment in this hospital in any way. Your doctor will still take care of you and you 
will not lose any benefits to which you are entitled. . 
 
6. Will your personal details be kept confidential?  
After the study is over the results of the study will be published in scientific journals. The 
names or identity of the participants will not be published. The hospital records will be 
kept confidential in the Department of Ophthalmology. Interested patients can be briefed 
about the results of the study. However, your medical notes may be reviewed by people 
associated with the study, without your additional permission, should you decide to 
participate in this study. 
If you have any further questions, you may contact Dr.Sherina Thomas.( Tel : 0416 
2281201) or email : sherinat4488@gmail.com 
Thank you for taking time to consider this study. 
If you wish to take part, please sign the attached consent form. 
This information sheet is for you to keep.  
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4.Informed Consent form to participate in a research study 
Study Title: 
Change in scar characteristics and visual outcome in patients with healed infective 
keratitis. 
Study Number: ____________ 
Subject’s Initials: __________________ Subject’s Name: 
____________________________ 
Date of Birth / Age: ___________________________ 
Subject- Consent for participating in the corneal scar study. 
(i) I confirm that I have read and understood the information sheet dated ____________ 
for the above study and have had the opportunity to ask questions. [  ] 
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected. [  ] 
(iii) I understand that, the Ethics Committee and the regulatory authorities will not need 
my permission to look at my health records both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the trial. I 
agree to this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published. [  ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [  ] 
(v) I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
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5.  INFORMATION SHEET ON CORNEAL TRANSPLANTATION: 
• What is corneal transplantation? 
   It’s the operation to replace the diseased cornea (anterior transparent part of eye) with a 
cornea which has been donated by a deceased person. The donated cornea is processed 
and tested for safety and good health before transplantation. (diagram). During the 
surgery the diseased (often opaque) cornea of the patient is removed and replaced by the 
clear transparent cornea of the donor, which is stitched together. 
 
 
 
• What is the use of corneal transplantation? 
The procedure helps different patients in different ways. These include healing of an 
ulcer, maintaining the shape of the eyeball, restoring vision and cosmesis. 
 
• How is the follow up after the procedure? 
It will need regular follow up, initially weekly followed by monthly and may need upto a 
year or more than that. 
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• What is the cost involved? 
    21000-24000/- 
 
• What are the complications? 
Complications include-fluid leaking from the stitched wound, infection, large amount of 
refractive error, cataract, glaucoma, scarring, rejection of graft and failure. 
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6.LOG MAR VISUAL ACUITY CHART 
 
 
 
 
 
 
 
 
 
 
7. LANG I STEREOTEST 
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8. ESTERMAN BINOCULAR FIELD 
 
 
 
 
 
 
 
 
 
9. BRIGHTNESS ACUITY TESTER 
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10. CORNEAL SCAR GRADING-AS DIVIDED INTO 3 GROUPS 
 
Involvement of 
central visual 
axis 
NEBULA-A MACULA-B LEUCOMA-C 
1( 0% ) 1a 1b 1c 
2 (upto 25%) 2a 2b 2c 
3 (upto 50%) 3a 3b 3c 
4(upto 99%) 4a 4b 4c 
5 (100%) 5a 5b 5c 
 
GROUP A-1a, 2a, 3a, 4a, 5a 
GROUP B-1b, 2b, 3b, 4b, 5b 
GROUP C-1c, 2c, 3c, 4c,5c 
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EXCEL DATA SHEET 
SN
O 
FUND
US HN 
AG
E 
F
I 
C
I 
SE
X 
SYSTEM
IC 
EY
E 
MICR
O 
SPECI
ES 
TIM
E 
VER
T 
HORI
Z 
SE
S 
TREATME
NT 
V6
7 
V6
8 
STEROI
DS 
V1
H 
V3
M
2 1 
52278
9S 46 1 2 2 4 1 5 1 4 2.8 0.5 4 5 7 
 
2 0.7 
1 2 
52356
1S 55 1 2 1 4 1 1 1 2 3.8 2.3 4 4 7 
 
2 
0.7
2 
 
3 1 
51570
9S 54 1 2 2 4 1 2 6 4 1.9 1 4 7 
  
2 0.9 
4 1 
51892
0S 53 1 2 2 4 1 1 1 8 4.3 3.5 4 7 8 
 
2 0.9 
 
5 1 
37782
0S 63 1 1 2 4 1 4 2 4 2.2 1.8 4 2 3 
 
2 0.4 
 
6 1 
52690
4S 66 1 1 2 4 2 5 1 4 1.8 3.2 4 11 
  
2 0.5 
7 4 
52299
6S 45 
 
2 2 4 2 2 5 6 5.3 5.8 4 7 8 
 
2 0.3 
8 2 
52047
4s 48 1 2 2 4 2 2 8 12 4.5 5.4 4 7 
  
2 0.8 
9 2 
50441
7s 20 1 2 2 4 1 2 6 12 3.7 3.6 4 7 8 12 2 
0.0
8 
10 1 
53199
2s 19 1 2 2 4 1 2 6 8 3.2 2.7 4 7 
  
2 0.2 
11 1 
53889
4s 18 1 1 1 4 1 1 1 1 1 1.2 4 1 3 
 
2 
0.0
2 
 
12 3 
53033
6s 55 1 2 2 4 1 1 1 16 6.5 7 4 7 8 
 
1 0.8 
 
13 4 
52499
8s 48 
 
2 1 4 2 1 1 8 4 4.2 4 4 
  
2 12 
14 2 
30806
6s 62 1 1 1 1 1 2 8 4 1 1 3 2 3 
 
2 0.2 
15 1 
53900
5s 48 1 1 1 4 1 6 4 2 3 2 4 2 
  
2 0 
16 1 
54110
1s 55 1 2 2 4 2 5 1 4 1.5 1.5 4 7 4 
 
2 0.8 
17 1 
53783
6s 28 1 2 1 4 1 2 6 4 2.6 3.8 4 7 
  
2 
0.2
6 
18 3 
50577
5s 54 1 2 1 4 2 6 9 24 5 6.5 4 2 7 
 
2 1.3 
19 1 
54029
8s 60 1 2 2 4 2 2 6 1 4 2.8 4 7 
  
2 
0.8
6 
 
20 4 
53588
5s 32 1 2 2 4 2 2 5 8 4.2 3 4 7 8 
 
2 
0.8
4 
 
21 3 
55878
8s 55 1 2 2 1 2 2 6 4 2.5 2 4 7 
  
2 1 
22 4 
53344
8s 55 
 
2 1 4 1 1 1 12 3.2 5.4 4 7 
  
2 1.3 
23 1 
54075
0s 78 1 2 1 4 1 2 6 2 2 1 4 7 
  
2 0 
24 2 
53472
7s 45 1 1 1 4 1 4 9 1 2 2 4 3 2 
 
1 0.4 
25 3 
53471
2s 45 
 
1 2 4 1 3 3 8 3.5 4 4 1 
  
1 0.8 
26 3 
53313
4s 36 1 1 2 4 2 5 1 24 3 3.1 4 5 
  
1 0.2 
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27 1 
54029
7s 35 1 2 2 4 2 2 6 2 3.3 2.3 4 7 
  
2 
0.1
4 
28 1 
54031
5s 64 1 2 1 4 1 2 6 3 5.5 1 4 7 8 5 2 0.7 
29 1 
30886
6S 62 1 1 1 1 1 2 8 4 1 1 4 2 
  
2 0.2 
30 1 
53900
5S 46 1 1 1 4 1 2 4 2 3 2 4 2 
  
2 0 
31 1 
54110
1S 55 1 2 2 4 2 5 1 4 1.5 1.5 4 7 
  
2 0.8 
32 1 
49219
5s 53 1 2 1 4 1 1 1 2 1.2 3.2 3 7 
  
2 0.1 
 
38 1 
56055
5s 50 1 2 1 4 1 2 9 4 3.8 2.6 5 8 
  
2 
0.3
4 
36 4 
54293
3s 66 2 2 1 4 2 2 8 8 6.5 6 5 7 4 8 2 1.3 
37 4 
53767
6s 48 
 
2 1 4 2 6 9 24 4.5 5 5 5 
  
1 1.3 
33 1 
53350
3s 46 1 2 1 4 1 2 6 4 1.5 1.5 4 7 
  
2 0 
34 1 
51859
0s 42 1 2 2 4 
 
2 10 4 1 1 4 2 8 
 
2 0 
35 1 
56026
6s 50 1 2 1 4 1 2 10 3 3.8 2.6 2 12 
  
2 
0.3
4 
39 1 
55528
5s 20 1 2 1 4 2 1 1 2 1.5 1.5 3 4 7 12 2 0.8 
40 1 
55834
5s 53 1 2 1 4 2 2 7 4 1.5 1 4 7 8 12 2 0.1 
 
41 1 
55801
5s 21 1 2 1 4 1 2 5 2 1.3 1 3 7 
  
2 0 
 
42 1 
56362
0s 43 1 2 2 4 2 5 1 4 2 1 4 7 
  
2 0.2 
43 1 
56256
9s 40 1 2 2 4 2 2 5 2 3 1 4 7 2 
 
2 0.3 
 
44 2 
55741
5s 60 1 2 2 4 2 1 1 2 3.5 3.7 1 7 
  
2 0.7 
45 1 
55119
0s 66 1 2 2 4 1 1 1 8 2.9 1.9 4 7 
  
2 0.3 
46 1 
55475
2s 38 1 2 2 4 1 1 1 4 2.2 1.6 4 7 8 12 2 0.1 
47 2 
56004
9s 62 1 2 1 4 1 2 5 4 2 2 4 7 
  
2 0 
48 3 
55752
4s 62 
 
2 2 1 1 2 6 5 3.2 3 3 7 10 12 1 0.3 
 
49 1 
55023
8s 51 1 2 1 4 2 2 6 8 3.5 1.5 4 7 
  
2 0.4 
50 3 
48536
3s 65 1 2 2 4 1 1 4 4 3 4 4 1 6 
 
1 
  
51 1 
50992
0s 66 1 1 1 4 1 1 1 8 3.5 3.5 4 2 3 4 1 
  
52 1 
50655
8s 49 1 2 2 4 1 2 1 4 3.5 2 2 7 
  
2 
  
53 3 
49541
9s 45 1 2 2 4 2 2 6 8 2.5 1.8 3 7 12 
 
2 
  
54 1 
44279
4s 24 1 2 1 4 1 1 1 3 2 1.5 3 7 8 
 
2 
  
55 1 
44461
4s 45 1 2 1 4 2 1 1 4 3 2 3 7 
  
2 
  
56 1 
51050
3s 45 1 1 2 4 2 1 1 4 3.5 4.5 4 5 
  
1 
  
57 3 
43334
2s 57 
 
2 1 4 2 2 6 4 5 5 4 7 12 
 
2 
  
58 2 
51542
4s 36 1 2 2 4 2 2 6 10 3.3 3.5 4 7 8 11 2 
  
59 1 
46219
2s 58 1 1 1 4 2 1 1 2 1 1 3 2 3 
 
1 
  
102 
 
66 1 
49219
8s 53 1 2 1 1 1 1 1 2 1.2 3.2 3 7 
  
2 
  
60 1 
42305
4s 44 1 1 2 4 2 1 1 2 1 1 4 5 
  
2 
  
61 1 
50431
9s 57 1 2 2 4 2 1 1 2 3.8 4.2 4 7 
  
2 
  
70 1 
51640
7s 43 1 2 1 4 2 1 1 4 2.5 1.3 4 7 
  
2 
  
63 4 
49702
8s 60 
 
1 1 4 1 1 1 8 5 4.5 4 3 2 
 
2 
  
64 1 
49573
9s 50 1 1 2 4 1 1 1 8 2 1 4 4 
  
1 
  
65 4 
53395
6s 75 
 
2 1 4 2 2 5 12 3.4 3.8 4 7 12 10 2 
  
67 1 
43357
2s 55 1 1 2 4 1 1 1 3 2.5 3 4 2 3 
 
2 
  
68 1 
43503
0s 66 1 2 2 1 1 2 6 4 2.5 3 4 7 
  
2 
  
69 1 
43168
8s 55 1 2 1 4 2 2 1 2 3 4 4 7 
  
2 
  
71 2 
42825
8s 54 1 1 1 4 2 1 1 3 4 2.5 4 2 3 
 
2 
   
SNO HN V3M V6M V1Y V2Y DEPTH THINNING POSITION S1H S3M S6M
2 522789S 0.7 
 
0.2 
 
1 1 3 2 2 
 
1 523561S 
  
0.56 
 
2 2 2 11 
  
3 515709S 0.9 
 
0.4 
 
3 2 3 3 3 
 
4 518920S 
 
0.9 
  
3 1 2 9 
 
5 377820S 
    
3 1 3 3 
  
6 526904S 0.66 0.66 0.66 
 
2 1 2 11 11 
7 522996S 0.3 
 
0.2 
 
3 3 1 14 14 
 
8 520474s 0.8 
   
3 1 2 11 11 
 
9 504417s 0.08 0.2 0.2 
 
1 1 2 5 5 
10 531992s 0.2 
   
1 2 2 5 5 
 
11 538894s 
    
1 1 3 3 
  
12 530336s 
  
0.3 
 
2 1 2 8 
  
13 524998s 12 12 
  
3 2 1 12 12 
14 308066s 0.4 
 
0.1 
 
2 1 3 2 2 
 
15 539005s 0 
   
2 1 2 2 2 
 
16 541101s 0.8 
   
1 1 3 5 5 
 
17 537836s 0.2 
   
2 1 2 8 8 
 
18 505775s 1.3 1.3 1.3 
 
3 3 1 15 15 
19 540298s 
 
0.8 
  
2 1 2 8 
 
20 535885s 
 
0.84 0.8 
 
3 1 2 12 
 
21 558788s 0.8 0.8 0.86 
 
1 1 2 8 8 
22 533448s 1.3 1.3 1.3 
 
2 1 1 15 15 
23 540750s 0 
 
0.01 
 
1 1 2 8 8 
 
24 534727s 0.1 
 
0.01 
 
3 1 2 5 5 
 
25 534712s 0.8 
 
0.7 
 
3 1 2 12 12 
 
26 533134s 0 0.2 
  
1 1 2 5 5 
103 
 
27 540297s 0.14 
 
0 
 
1 1 2 8 8 
 
28 540315s 0.7 
 
0.7 
 
1 1 3 2 2 
 
29 308866S 0.4 
   
2 1 3 2 2 
 
30 539005S 0 
   
2 1 2 2 2 
 
31 541101S 0.8 
   
1 1 3 5 5 
 
32 492195s 
  
0.1 0.1 1 1 3 1 
  
38 560555s 0.34 0.1 
  
1 1 2 8 8 
36 542933s 1.3 1.3 1.3 
 
5 2 1 15 15 
37 537676s 1.3 
 
1.3 
 
2 1 1 14 14 
 
33 533503s 0 
 
0 
 
2 1 3 2 2 
 
34 518590s 0 0 0 
 
1 1 3 3 3 
35 560266s 0.34 0.1 
  
1 1 2 8 8 
39 555285s 0.8 
 
0.1 
 
1 1 2 5 5 
40 558345s 
 
0.1 
  
1 1 3 2 
 
41 558015s 
 
0 
  
1 1 3 2 
 
42 563620s 0 0 
  
1 1 2 1 1 
43 562569s 
  
0.3 
 
1 1 2 5 
  
44 557415s 0.4 0.2 
  
1 1 2 11 11 
45 551190s 0.3 
   
1 1 2 11 11 
 
46 554752s 0 0 
  
1 1 3 3 3 
47 560049s 0 0.1 
  
1 1 2 8 8 
48 557524s 
 
0.94 
  
1 1 2 11 
 
49 550238s 0.1 0.1 
  
1 1 2 5 4 
50 485363s 
    
1 1 1 
   
51 509920s 
   
0.5 1 1 2 
   
52 506558s 
   
0.04 1 1 2 
   
53 495419s 
  
0.1 
 
1 1 3 
   
54 442794s 
   
0 1 1 3 
   
55 444614s 
   
1 1 1 2 
   
56 510503s 
  
0.34 
 
1 1 1 
   
57 433342s 
   
0.56 2 2 2 
   
58 515424s 
   
0.56 1 1 2 
   
59 462192s 
   
0.46 1 1 2 
   
66 492198s 
  
0.1 0.1 1 1 3 
   
60 423054s 
  
0.2 
 
1 1 1 
   
61 504319s 
  
0.76 
 
1 1 2 
   
70 516407s 
  
0 
 
1 1 3 
   
63 497028s 
    
2 2 1 
   
64 495739s 
   
0.1 1 1 3 
   
65 533956s 
    
3 2 1 
   
67 433572s 
  
0.36 
 
1 1 2 
   
68 435030s 
  
0.14 
 
1 1 2 
   
69 431688s 
  
0.4 
 
1 1 2 
   
104 
 
71 428258s 
  
0.42 
 
1 1 2 
   
62 505775s 
    
2 2 2 
    
SNO HN S6M S1Y S2Y GLUE CATARACT C1M C3M V39 C1Y C2Y
2 522789S 
 
1 
 
2 1 1 1 
 
2 
 1 523561S 
 
10 
 
2 1 1 
  
1 
 3 515709S 
 
2 
 
2 1 1 1 
 
8 
 4 518920S 9 
  
2 1 1 
 
1 
  5 377820S 
   
2 4 1 
    6 526904S 11 11 
 
2 2 1 2 2 2 
 7 522996S 
 
14 
 
2 1 1 1 
 
1 
 8 520474s 
   
2 2 2 2 
   9 504417s 5 4 
 
2 1 1 1 1 1 
 10 531992s 
   
2 1 1 1 
   11 538894s 
   
2 1 1 
    12 530336s 
 
7 
 
2 2 3 
  
8 
 13 524998s 12 
  
2 1 1 2 2 
  14 308066s 
 
1 
 
2 4 8 8 
 
8 
 15 539005s 
   
2 1 1 1 
   16 541101s 
   
2 4 8 8 
   17 537836s 
   
2 1 1 1 
   18 505775s 15 15 
 
2 4 8 8 8 8 
 19 540298s 8 
  
2 2 2 
 
2 
  20 535885s 12 11 
 
2 1 1 
 
1 2 
 21 558788s 8 7 
 
2 1 3 3 3 3 
 22 533448s 15 15 
 
2 6 9 9 9 9 
 23 540750s 
 
7 
 
2 1 1 1 
 
1 
 24 534727s 
 
5 
 
2 1 1 1 
 
1 
 25 534712s 
 
12 
 
2 1 1 2 
 
2 
 26 533134s 5 
  
2 1 1 1 1 
  27 540297s 
 
4 
 
2 1 1 
  
1 
 28 540315s 
 
2 
 
2 2 2 4 
 
4 
 29 308866S 
   
2 4 8 8 
   30 539005S 
   
2 1 1 1 
   31 541101S 
   
2 4 8 8 
   32 492195s 
 
1 1 2 1 1 
  
1 
38 560555s 8 
  
2 1 1 1 1 
  36 542933s 15 
  
2 6 9 9 9 
  37 537676s 
 
14 
 
2 6 8 8 
 
8 
 33 533503s 
 
1 
 
2 1 1 1 
 
1 
 34 518590s 2 1 
 
2 1 1 1 1 1 
 35 560266s 8 
  
2 1 1 1 1 
  
105 
 
39 555285s 5 
  
2 1 1 1 1 
  40 558345s 1 
  
2 1 1 
 
1 
  41 558015s 2 
  
2 1 1 
 
1 
  42 563620s 1 
  
2 1 1 1 1 
  43 562569s 
 
4 
 
2 1 1 
  
1 
 44 557415s 11 
  
2 2 2 2 2 
  45 551190s 
   
2 1 1 1 
   46 554752s 2 
  
2 1 2 2 2 
  47 560049s 8 
  
2 2 2 2 2 
  48 557524s 11 
  
2 2 3 
 
4 
  49 550238s 4 
  
2 1 1 1 1 
  50 485363s 
 
11 
 
2 2 
   
4 
 51 509920s 
  
5 2 2 
    
52 506558s 
  
5 2 2 
    
53 495419s 
 
2 
 
2 1 
   
1 
 54 442794s 
  
1 2 1 
   
1 
 55 444614s 
  
8 2 1 
    
56 510503s 
 
11 
 
2 4 
   
8 
 57 433342s 
  
8 2 2 
    
58 515424s 
  
11 2 1 
    
59 462192s 
  
1 2 2 
    
66 492198s 
 
1 1 2 1 
   
1 
60 423054s 
 
2 
 
2 1 
   
1 
 61 504319s 
 
11 
 
2 2 
   
4 
 70 516407s 
 
10 
 
2 1 
   
1 
 63 497028s 
  
14 2 2 
    
64 495739s 
  
1 2 4 
    
65 533956s 
 
9 
 
2 1 
   
1 
 67 433572s 
 
8 
 
2 1 
   
1 
 68 435030s 
 
5 
 
2 1 
   
1 
 69 431688s 
 
8 
 
2 2 
   
2 
 71 428258s 
 
8 
 
2 1 
   
1 
 62 505775s 
 
12 
 
2 6 
   
9 
 SNO HN C2Y G1H VG3M G6M G1Y G2Y E1H E3M E6M E1Y
2 522789S 
 
0.82 0.74 
 
0.14 
 
100 100 
 
1 523561S 
 
0.96 
  
0.7 
 
98 
  
3 515709S 
 
0.96 0.94 
 
0.34 
 
98 98 
 
4 518920S 
 
0.87 
 
0.86 
      5 377820S 
 
0.6 
    
100 
   6 526904S 
 
0.76 0.3 0.28 0.44 
 
99 100 100 
7 522996S 
 
2 2 
 
2 
 
98 98 
 
8 520474s 
 
0.94 0.94 
   
98 96 
  9 504417s 
 
0.16 0.16 0.3 0.16 
 
100 99 99 
106 
 
10 531992s 
 
0.2 0.2 
   
100 100 
  11 538894s 
 
0.06 
    
100 
   12 530336s 
 
0.6 
  
0.24 
 
0 
  
13 524998s 
      
97 96 93 
 14 308066s 
 
0.2 0.16 
 
0.06 
 
100 100 
 
15 539005s 
 
0.1 0.1 
   
90 96 
  16 541101s 
 
1 1 
   
100 100 
  17 537836s 
 
0.3 0.3 
   
100 100 
  18 505775s 
 
1.3 1.3 1.3 1.3 
 
74 
  
19 540298s 
 
0.9 
 
0.9 
  
80 
 
90 
 20 535885s 
 
0.9 
 
0.9 0.9 
 
100 
 
84 
21 558788s 
 
0.94 0.9 0.9 0.96 
 
99 100 100 
22 533448s 
 
1.3 1 1.3 1.3 
 
90 90 98 
23 540750s 
 
0 0.06 
 
0.06 
 
99 100 
 
24 534727s 
 
0.6 0.2 
 
0.06 
 
100 100 
 
25 534712s 
 
0.9 0.9 
 
0.8 
 
90 97 
 
26 533134s 
 
0.4 0.1 0.1 
  
99 100 100 
 27 540297s 
 
0.26 0.26 
 
0 
 
100 100 
 
28 540315s 
 
1 1 
 
1 
 
62 59 
 
29 308866S 
 
0.18 0.16 
   
100 100 
  30 539005S 
 
0.1 0.1 
   
90 99 
  31 541101S 
 
1 1 
   
100 100 
  32 492195s 1 0.1 
  
0.1 0.1 99 
  
38 560555s 
 
0.3 0.3 0.3 
  
100 100 100 
 36 542933s 
 
1.3 1.3 0.3 1.3 
 
83 85 85 
 37 537676s 
 
1.3 1.3 
 
1.3 
 
88 88 
 
33 533503s 
 
0 0 
 
0 
 
90 91 
 
34 518590s 
 
0 0 0 0 
 
100 100 100 
35 560266s 
 
0.3 0.3 0.3 
  
100 100 100 
 39 555285s 
 
0.66 0.66 0.66 
  
100 100 100 
 40 558345s 
 
0.06 
 
0.08 
  
100 
 
100 
 41 558015s 
 
0 
 
0 
  
100 
 
100 
 42 563620s 
 
0.16 0 0 
  
31 99 99 
 43 562569s 
 
0.4 
  
0.26 
 
100 
  
44 557415s 
 
0.76 0.36 0.2 
  
100 100 100 
 45 551190s 
 
0.5 0.46 
   
100 100 
  46 554752s 
 
0.1 0 0 
  
93 100 100 
 47 560049s 
 
0.06 0.06 0.1 
  
98 98 96 
 48 557524s 
 
0.28 
 
0.92 
  
57 
 
69 
 49 550238s 
 
0.36 0.06 0.06 
  
100 100 100 
 50 485363s 
         
51 509920s 3 
    
0.54 
    52 506558s 3 
    
0.14 
    
107 
 
53 495419s 
    
0.1 
    
54 442794s 
    
0 
     55 444614s 1 
    
0.94 
    56 510503s 
    
0.4 
    
57 433342s 3 
    
0.6 
    58 515424s 2 
    
0.6 
    59 462192s 2 
    
0.5 
    66 492198s 1 
   
0.1 0.1 
   
60 423054s 
    
0.16 
    
61 504319s 
    
0.9 
    
70 516407s 
    
0 
    
63 497028s 6 
         64 495739s 8 
    
0.2 
    65 533956s 
         
67 433572s 
    
0.4 
    
68 435030s 
    
0.26 
    
69 431688s 
    
0.56 
    
71 428258s 
    
0.5 
    
62 505775s 
         
2 522789S E1H E3M E6M E1Y E2Y ST1H VST3M ST6M ST1Y ST2Y
1 523561S 100 100 
 
95 
 
1 1 
 
1 
 
3 515709S 98 
  
99 
 
4 
  
4 
 
4 518920S 98 98 
 
90 
 
1 1 
 
3 
 
5 377820S 
     
4 
 
4 
  
6 526904S 100 
    
1 
    
7 522996S 99 100 100 96 
 
1 1 1 1 
 
8 520474s 98 98 
 
100 
 
2 2 
 
2 
 
9 504417s 98 96 
   
2 2 
   
10 531992s 100 99 99 100 
 
1 1 1 1 
 
11 538894s 100 100 
   
1 1 
   
12 530336s 100 
    
1 
    
13 524998s 0 
  
80 
 
4 
  
4 
 
14 308066s 97 96 93 
  
4 4 4 
  
15 539005s 100 100 
 
100 
 
1 1 
 
1 
 
16 541101s 90 96 
   
1 1 
   
17 537836s 100 100 
   
1 1 
   
18 505775s 100 100 
   
1 1 
   
19 540298s 74 
  
76 
 
4 4 4 4 
 
20 535885s 80 
 
90 
  
4 
 
4 
  
21 558788s 100 
 
84 100 
 
3 
 
3 3 
 
22 533448s 99 100 100 99 
 
1 1 
 
1 
 
23 540750s 90 90 98 98 
 
4 4 4 4 
 
24 534727s 99 100 
 
100 
 
1 1 
 
1 
 
108 
 
25 534712s 100 100 
 
100 
 
1 1 
 
1 
 
26 533134s 90 97 
 
98 
 
4 4 
 
4 
 
27 540297s 99 100 100 
  
1 1 1 
  
28 540315s 100 100 
 
100 
 
1 1 
 
1 
 
29 308866S 62 59 
 
99 
 
1 1 
 
1 
 
30 539005S 100 100 
   
1 1 
   
31 541101S 90 99 
   
1 1 
   
32 492195s 100 100 
   
1 1 
   
38 560555s 99 
  
99 100 1 
  
1 
36 542933s 100 100 100 
  
1 1 1 
  
37 537676s 83 85 85 
  
4 4 4 
  
33 533503s 88 88 
 
89 
 
4 4 
 
4 
 
34 518590s 90 91 
 
100 
 
1 1 
 
1 
 
35 560266s 100 100 100 100 
 
1 1 1 1 
 
39 555285s 100 100 100 
  
1 1 1 
  
40 558345s 100 100 100 
  
2 2 2 
  
41 558015s 100 
 
100 
  
1 
 
1 
  
42 563620s 100 
 
100 
  
1 
 
1 
  
43 562569s 31 99 99 
  
1 1 1 
  
44 557415s 100 
  
96 
 
1 
  
1 
 
45 551190s 100 100 100 
  
2 2 2 
  
46 554752s 100 100 
   
1 1 
   
47 560049s 93 100 100 
  
1 1 1 
  
48 557524s 98 98 96 
  
1 1 1 
  
49 550238s 57 
 
69 
  
4 
 
4 
  
50 485363s 100 100 100 
  
1 1 1 
  
51 509920s 
   
80 
    
4 
 
52 506558s 
         
53 495419s 
    
100 
    
54 442794s 
   
98 
    
1 
 
55 444614s 
    
100 
    
56 510503s 
    
100 
    
57 433342s 
   
100 
    
1 
 
58 515424s 
    
97 
    
59 462192s 
    
99 
    
66 492198s 
    
85 
    
60 423054s 
   
99 100 
   
1 
61 504319s 
   
100 
    
3 
 
70 516407s 
   
90 
    
1 
 
63 497028s 
   
98 
    
1 
 
64 495739s 
    
90 
    
65 533956s 
    
0 
    
67 433572s 
   
90 
    
4 
 
109 
 
68 435030s 
   
80 
    
4 
 
69 431688s 
   
99 
    
3 
 
71 428258s 
   
86 
    
1 
 
62 505775s 
   
80 
    
1 
 
     
50 
    
4 
 
S.NO 
HOSP 
NO ST2Y V57 V59 V58 V60 V61 V62 V56 V54 V55 V63 V64 V65 V66 
2 522789S 1 1 1 2 
  
6.9 6.6 -2 1 2 
 
3 
1 523561S 1 1 1 2 
  
6.18 6.6 -2 2 2 
 
3 
3 515709S 1 1 1 2 
  
6.12 2.6 
 
2 2 
 
3 
4 518920S 1 1 1 
   
6.36 6.9 
 
2 2 
 
3 
5 377820S 
             
6 526904S 1 1 1 2 
  
6.12 6.6 -2 2 2 
 
3 
7 522996S 1 1 
 
2 
  
6.6 1 -1 1 2 
 
3 
8 520474s 
 
1 1 
    
6.18 6.6 
 
2 2 
 
3 
9 504417s 
 
1 1 1 2 
  
6.6 6.6 -1.5 1 2 
 
3 
10 531992s 
 
1 1 1 
   
6.9 6.6 
 
2 2 
 
3 
11 538894s 
              
12 530336s 
 
11 1 1 2 
  
6.9 6.9 -3.5 2 2 
 
3 
13 524998s 
 
4 1 3 2 
  
1.6 6.6 
 
2 
  
2 
14 308066s 
 
1 1 1 1 1 1 6.6 6.6 -1.25 1 2 
 
3 
15 539005s 
 
1 1 1 
   
6.9 6.6 
 
1 2 
 
3 
16 541101s 
 
1 1 1 2 
  
6.36 6.6 
 
2 2 
 
3 
17 537836s 
 
1 1 1 2 
  
6.96 6.6 
 
1 2 
 
3 
18 505775s 
 
4 1 
 
1 1 1 1.6 6.12 1 2 1 1 
 
19 540298s 
 
1 1 1 2 
  
6.36 6.9 
 
2 2 
 
2 
20 535885s 
 
1 1 1 2 
  
6.18 6.6 
 
1 2 
 
3 
21 558788s 
 
2 1 1 2 
  
6.66 612 
 
1 2 
 
2 
22 533448s 
 
4 1 5 2 
  
1.6 6.12 
 
2 2 
 
5 
23 540750s 
 
1 1 1 2 
  
6.6 6.6 
 
1 2 
 
3 
24 534727s 
 
1 1 1 2 
  
6.6 6.6 
 
2 2 
 
3 
25 534712s 
 
1 1 1 2 
  
6.24 6.6 
 
2 2 
 
3 
26 533134s 
 
1 1 1 
   
6.9 6.6 
 
2 2 
 
3 
27 540297s 
 
1 1 1 2 
  
6.6 6.6 -1 2 2 
 
3 
28 540315s 
 
1 1 2 2 
  
6.18 6.12 3 1 2 
 
5 
29 308866S 1 
 
1 2 
  
6.12 6.6 -1 2 2 
 
3 
30 539005S 1 1 1 2 
  
6.9 6.6 
 
2 2 
 
3 
31 541101S 1 1 1 2 
  
6.36 6.6 -1 1 2 
 
3 
32 492195s 1 1 1 1 2 
  
6.6 6.6 -0.5 2 2 
 
3 
38 560555s 
 
1 1 1 2 
  
6.6 6.6 -4 1 2 
 
3 
36 542933s 
 
no 1 2 2 
  
1.6 6.12 
 
2 1 1 
 
37 537676s 
 
no  1 4 2 
  
1.6 6.9 
 
2 1 1 
 
33 533503s 
 
1 1 1 
   
6.6 6.6 
 
2 2 
 
3 
110 
 
34 518590s 
 
1 1 1 2 
  
6.6 6.6 
 
1 2 
 
3 
35 560266s 
  
1 1 2 
  
6.6 6.6 -4 1 2 
 
3 
39 555285s 
 
1 1 1 2 
  
6.6 6.6 
 
1 2 
 
3 
40 558345s 
 
1 1 3 2 
  
6.6 6.6 
 
2 2 
 
3 
41 558015s 
 
1 1 1 2 
  
6.6 6.6 
 
2 2 
 
3 
42 563620s 
 
1 2 1 2 
  
6.6 6.6 
 
1 2 
 
3 
43 562569s 
 
1 1 1 1 1 1 6.9 6.6 
 
1 2 
 
3 
44 557415s 
 
1 1 1 2 
  
6.9 6.6 -2 2 2 
 
3 
45 551190s 
 
1 1 1 2 
  
6.12 6.9 -2.5 2 2 
 
3 
46 554752s 
 
1 1 1 2 
  
6.6 6.6 
 
2 2 
 
3 
47 560049s 
 
1 1 1 2 
  
6.6 6.6 -0.75 2 2 
 
3 
48 557524s 
 
2 1 3 1 1 1 6.66 6.9 
 
1 2 
 
5 
49 550238s 
 
1 1 1 2 
  
6.6 6.6 
 
2 2 
 
3 
50 485363s 
 
1 1 3 2 
  
2.6 6.12 
 
2 2 
 
2 
51 509920s 4 1 1 1 2 
  
6.12 6.18 -2.5 2 2 
 
3 
52 506558s 2 1 1 1 2 
  
6.9 6.6 
 
1 2 
 
3 
53 495419s 
 
1 1 1 2 
  
6.6 6.6 
 
1 2 
 
3 
54 442794s 1 1 1 1 2 
  
6.6 6.6 
 
2 2 
 
3 
55 444614s 4 3 1 3 2 
  
6.12 6.6 
 
2 2 
 
5 
56 510503s 
 
1 1 1 2 
  
6.12 6.6 
 
2 2 
 
3 
57 433342s 1 1 1 2 1 3 2 6.18 6.9 -1.5 2 2 
 
3 
58 515424s 1 1 1 1 2 
  
6.24 6.18 
 
1 2 
 
3 
59 462192s 4 1 1 1 2 
  
6.9 1.6 
 
2 2 
 
3 
66 492198s 1 1 1 1 2 
  
6.6 6.6 -0.5 2 2 
 
3 
60 423054s 
 
1 1 1 2 
  
6.6 6.6 
 
1 2 
 
3 
61 504319s 
 
1 1 1 1 1 1 6.24 6.6 
 
2 2 
 
3 
70 516407s 
 
1 1 1 2 
  
6.6 6.6 
 
1 2 
 
3 
63 497028s 4 4 1 2 1 1 4 1.6 6.6 
 
2 2 
 
4 
64 495739s 4 1 1 1 2 
  
6.6 6.9 -1.25 1 2 
 
3 
65 533956s 
 
4 1 2 1 1 1 1.6 6.6 
 
2 1 1 
 
67 433572s 
 
1 1 1 1 1 1 6.12 6.9 -1 2 2 
 
3 
68 435030s 
 
1 1 1 2 
  
6.9 6.6 
 
2 2 
 
3 
69 431688s 
 
1 1 1 2 
  
6.18 6.12 
 
1 2 
 
5 
71 428258s 
 
1 1 1 1 2 1 6.18 6.6 -1 2 2 
 
3 
62 505775s 
 
4 1 2 2 
  
1.6 6.12 
 
2 2 
 
2 
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